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 Spleen tyrosine kinase (SYK) regulates mitogenic signaling, inflammatory 
responses and cell fate in a number of diverse cell types. KRAS is a proto-oncogene that 
controls cell growth and proliferation through several mitogenic pathways. In pancreatic 
cancer, KRAS is frequently mutated, resulting in constitutive activation in 90% of 
pancreatic cancer cell lines. We previously showed that SYK is highly expressed in a 
subset of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cell lines. We 
demonstrated that SYK kinase inhibition with PRT062607 (SYKi) causes decreased cell 
proliferation of PDAC cell lines. Furthermore, combined SYKi and MEK inhibitor 
(MEKi) treatment promotes additive effects on suppression of PDAC cell proliferation 
and clonogenic growth. Mechanistically, SYK activates the mTORC1 kinase complex as 
shown by reduced phosphorylation of ribosomal S6 protein and its upstream kinase p70 
S6 kinase (p70S6K) following SYKi treatment in PDAC cell lines. SYK-mediated 
mTORC1 activation occurs independently of MEK/ERK and PI3K/AKT effector 
signaling pathways. The mTORC1 complex suppresses lysosome biogenesis and 
 
 viii 
macroautophagy (autophagy). Consequently, mTORC1 suppression via SYK inhibition 
or shRNA-mediated depletion causes accumulation of autolysosomes. These effects are 
mediated by the enhanced nuclear localization of MITF, a key transcriptional regulator of 
genes involved in lysosome biogenesis and autophagy pathway activation. In summary, 
SYK positively regulates mTORC1 activation in a subset of PDAC cell lines to suppress 
hyperactivation of autophagy. These findings open new avenues for further exploration of 
SYK as a critical regulator of the autophagy pathway in KRAS/mTORC1-dependent 
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CHAPTER ONE: INTRODUCTION 
Pancreatic cancer 
Overview 
 The pancreas is a glandular organ with both endocrine and exocrine functions [1, 
2]. Its overall purpose is to maintain metabolic homeostasis by producing hormones that 
regulate blood glucose levels as well as enzymes that aid in digestion. The pancreas is 
derived from the embryonic foregut of the endodermal germ layer [3]. During embryonic 
development, two buds that ultimately give rise to the dorsal and ventral pancreas emerge 
from the foregut. As these buds expand, they are gradually repositioned over time until 
they come into contact and fuse together, forming the mature pancreas. Under the control 
of various developmental cues, pancreatic progenitor cells become acinar, endocrine, or 
ductal in function. Endocrine cells (α, β, and δ) secrete hormones like insulin, glucagon, 
and somatostatin into the circulatory system to modulate blood glucose levels [1]. This 
homeostatic function ensures that the metabolic demands of various tissues and organs 
are met. Acinar cells in the ducts secrete enzymes like trypsinogen, chymotrypsinogen, 
lipase, and amylase into the pancreatic duct [2]. These enzymes subsequently enter into 
the small intestine, where they aid in the digestion of various dietary macromolecules 
such as proteins, carbohydrates, and lipids. 
 Pancreatic dysfunction can lead to a number of common diseases including 
diabetes, pancreatitis, and cancer [4-6]. Diabetes is the most prevalent of these diseases. 
However, cancer of the pancreas is by far the deadliest, and its etiology is often linked to 




cause of cancer-related deaths in the United States and is associated with a particularly 
poor prognosis [7]. Patients diagnosed with this disease exhibit a median overall survival 
of less than 6 months and a 5-year survival rate of roughly 8%. The poor prognosis 
associated with pancreatic cancer is attributed in part to poor methods of early detection 
[8]. Patients often remain asymptomatic until the disease has disseminated throughout the 
body. Additionally, the therapeutics used to treat pancreatic cancer are relatively 
ineffective, as they fail to extend patient survival more than several months [9]. 
Overcoming these challenges will be critical in the future treatment of the disease, as it is 
expected to become the second leading cause of cancer-related deaths in the United 
States by 2030 [10]. 
 Pancreatic cancers can arise from either endocrine or exocrine cells. Thus, 
endocrine and exocrine tumors can be distinguished by histological appearance. 
Endocrine tumors are relatively uncommon and constitute less than 5% of all pancreatic 
cancers. They are associated with a median survival of 27 months and a 0.28-fold lower 
risk of mortality in comparison to the much more common pancreatic adenocarcinoma 
[11]. Endocrine tumors are commonly derived from pancreatic islet cells and often 
produce constitutively high levels of pancreatic hormones. They can be further 
categorized into insulinomas, glucagonomas, and gastrinomas depending on their cell of 
origin and the hormones that they secrete. Pancreatic endocrine tumors can be readily 
diagnosed due to their excessive hormone secretion, which leads to dramatic symptoms 
such as hypoglycemia or necrolytic migratory erythema (skin rash) [12]. Pancreatic 




can typically be classified into two histological subtypes. The pancreatic ductal 
adenocarcinoma (PDAC) subtype accounts for the majority of exocrine tumors and 
constitutes more than 90% of all pancreatic malignancies. PDACs are derived from 
epithelial cells that line the pancreatic duct and appear gland-like due to their origin [11]. 
These cancers frequently metastasize to the liver or lymph nodes [13]. Due to their lack 
of symptoms at the early stages of cancer development, PDACs are often diagnosed at a 
late stage, potentially after the cancer has already metastasized. As a result, anticancer 
therapeutics tend to be weakly effective due to the cancers having acquired strong 
cytoprotective mechanisms that promote drug resistance. Because of this aggressiveness 
and drug resistance, estimated median survival for PDAC can be as short as 4 months 
[11]. 
 PDACs are preceded by the development of hyperplastic lesions known as 
pancreatic intraepithelial neoplasias (PanINs) and intraductal papillary mucinous 
neoplasms (IPMNs) that are precancerous and exhibit a propensity to develop into cancer 
(Fig. 1.1). IPMNs look like papillae (finger-like structures) that protrude into the 
pancreatic duct [14]. Mucinous tumors are the second most common histological subtype 
of pancreatic cancer, constituting less than 10% of cases. These tumors are usually much 
less invasive than adenocarcinomas at the time of diagnosis and have a 0.88-fold lower 
risk of mortality by comparison [11]. Mucinous tumors also originate from the pancreatic 
ductal epithelium, but secrete mucin, which can be seen in and around the cells, causing 




pancreatic cancer, such as those that arise from acinar cells, which are undifferentiated 
and resemble liver cancers. However, these subtypes are rare. 
 
Figure 1.1. Disease progression model of pancreatic cancer. 
Pancreatic cancer arises from two histological types of precursor lesions: PanINs and IPMNs. Through progressive 
stages of pathogenesis, molecular changes occur, leading to increasing degrees of nuclear and cytoskeletal 
abnormalities. Genetic alterations commonly observed in these lesions are indicated with respect to the stages in which 





Oncogenic KRAS mutations 
 Whole exome-sequencing studies have revealed that PDAC is a molecularly 
heterogeneous disease characterized by four common genetic alterations: oncogenic 
KRAS mutation and inactivation of the tumor suppressors CDKN2A, TP53, and SMAD4 
(Figs. 1.1 and 1.2A) [6]. However, myriad additional genes are mutated in subsets of 
tumors, typically at a very low frequency (10%), with many of these mutations not 
occurring in a recurrent manner. Further analysis of these infrequent alterations has 
revealed that they converge on a relatively small number of pathways and cellular 
processes including KRAS, transforming growth factor-β (TGF-β), WNT, NOTCH, and 
Hedgehog signaling as well as S-phase entry, axonal guidance, chromatin remodeling, 
DNA repair, and RNA processing [17, 18]. Understanding how context-dependent 
interactions between these various genetically altered pathways contribute to PDAC 
progression is a key goal in the development of more selective and efficacious 
therapeutic modalities to treat the disease. 
 Activating KRAS mutations are the defining genetic feature of PDAC progression 
and are found in approximately 92% of PDAC [18]. KRAS, a member of the RAS 
superfamily, encodes a small GTPase that regulates diverse cellular processes including 
cell proliferation, differentiation, survival, and migration (Fig. 1.2A) [19]. Under normal 
physiological conditions, KRAS cycles through a GTP-bound active state and a GDP-
bound inactive state. The transition between these two states is modulated by guanine 
nucleotide exchange factors (GEFs; e.g., Sos1), which catalyze the exchange of GDP for 




weak ability of KRAS to hydrolyze GTP [20, 21]. In quiescent cells, KRAS is 
predominantly GDP bound. However, upon growth factor stimulation, GEFs are able to 
bind to KRAS and promote its activation by catalyzing GDP–GTP exchange. In many 
solid cancers, KRAS or one of its closely related family members (HRAS and NRAS) 
undergo mutations that ultimately impair their ability to hydrolyze GTP. HRAS and 
NRAS mutations are typically not found in PDAC. Oncogenic RAS proteins are locked 
in an active state that results in constitutive stimulation of effector pathways capable of 
driving tumor development [22]. The major effector pathways downstream of active RAS 
are those mediated by RAF/MEK/ERK, PI3K, and RAL-GEF. 
 KRAS point mutations typically result in a single amino acid substitution at one 
of the three codons: G12, G13, or Q61 [21]. All three substitutions occur in the catalytic 
domain of the GTPase. G12 and G13 mutations introduce a steric hindrance that blocks 
the formation of van der Waals interactions between KRAS and GAPs [23]. Q61 
mutations disrupt the coordination of a water molecule required for GTP hydrolysis [24]. 
Although all three mutations promote KRAS activation by impairing its GTPase activity, 
the frequencies at which they occur are vastly disparate. Substitutions at codon G12 
(typically G12D or G12V) are the most prevalent (82%) followed by Q61 (14%) and G13 
(<1%) [21]. Interestingly, the three common KRAS mutant alleles exhibit contrasting 
functional properties. Tumors harboring KRAS Q61 substitutions display reduced MAPK 
activity and are associated with a better prognosis than substitutions at other codons [25]. 
This suggests that different KRAS mutations promote tumorigenesis in distinct ways.




of almost all PDACs (Fig. 1.1), as they are prevalent in greater than 90% of low-grade 
precursor PanIN lesions [26]. PDAC is preceded by the emergence of PanIN lesions, 
which are classified into three stages (I–III) based on the degree of architectural 
disorganization and nuclear abnormalities of the tissue [6]. In vivo studies of genetically 
engineered mouse models (GEMMs) have demonstrated that PanINs readily develop as a 
consequence of KRAS-activating mutations but do not ultimately give rise to PDAC. 
Rather, the subsequent and combined inactivation of multiple tumor suppressor genes 
(TSGs; i.e., CDK2NA, TP53, and SMAD4) is also required for malignant tumor 
progression [6, 27, 28]. These findings suggest that KRAS mutations alone are not 
sufficient to promote PDAC progression. 
 Although oncogenic KRAS promotes the initiation of PDAC development, its 
role in tumor maintenance is less clear. In a GEMM of PDAC, pancreas-specific 
induction of KRASG12D expression coupled with loss of a single TP53 allele results in the 
dedifferentiation of normal epithelial cells and the development of PanINs [29]. 
Extinction of oncogenic KRAS leads to the regression of these lesions, suggesting that it 
is required for PanIN progression. In a subsequent study, pancreas-specific induction of 
KRASG12D expression coupled with the loss of one or both TP53 alleles led to the 
development of PDAC [30]. Similar to the effects observed in PanINs. Extinction of 
oncogenic KRAS in these PDAC lesions led to robust tumor regression. Taken together 





 In contrast to observations using GEMMs, which bear similarities to subsets of 
human PDAC, alternative studies using human PDAC-derived cancer cell lines suggest 
that KRAS is dispensable in certain contexts [31, 32]. Approximately half of human-
derived PDAC cell lines readily undergo apoptosis following RNAi-mediated depletion 
of the GTPase, indicating a state of KRAS oncogene “dependency.” The discrepancy 
between these findings and those obtained in the GEMM studies may be attributed to a 
number of factors. First, pharmacological vulnerabilities in GEMMs do not often 
translate to clinical trials of human cancers, as has been observed with inhibitors of the 
MAPK and PI3K pathways [20]. This suggests that, although the same defined genetic 
mutations from human PDAC promote disease development in GEMMs, the resulting 
tumors likely display altered molecular characteristics compared to their human 
counterparts. Another potential explanation for the discrepancy between mouse and 
human cell line models is that some GEMM-derived tumors may be transiently 
dependent on KRAS during early stages of PDAC progression. In mouse xenografts, 
MAPK, PI3K, and RalGEF are all required for tumor initiation [33]. However, only the 
PI3K pathway is necessary for tumor maintenance, suggesting a reduced need for 
oncogenic KRAS. Furthermore, activation of PI3K/AKT signaling by the tumor 
microenvironment is able to rescue the loss of mutant KRAS. This suggests that KRAS 
may become dispensable in the later stages of PDAC progression if the PI3K pathway is 
activated. Such a context may be difficult to model in GEMMs due to the rapid disease 




 More recent studies in GEMMs have demonstrated that the need for KRAS can be 
bypassed by enhanced mitochondrial activity or Hippo pathway deregulation [34-36]. In 
both cases, depletion of the KRAS protein resulted in robust tumor regression, consistent 
with previous in vivo work. However, subpopulations of cells were able to drive tumor 
relapse. In the case of Hippo pathway deregulation, surviving cells expressed lower 
KRAS protein levels and were unresponsive to KRAS depletion. Furthermore, the 
relapsed tumors exhibited a more mesenchymal morphology, reminiscent of the 
phenotype observed in PDAC cell lines that were insensitive to KRAS depletion [31]. 
Similarly, surviving cells that bypassed KRAS dependence by increased oxidative 
phosphorylation were also more stem-like in morphology. Taken together, these studies 
demonstrate that KRAS may be dispensable in subsets of tumors or subsets of cells 
within a tumor that can bypass the dependence on oncogenic KRAS signaling. As 
discussed later, this poses a new challenge to developing effective therapies to treat 





Figure 1.2. Deregulated signaling networks in pancreatic cancer. 
A. RTK and cell cycle regulatory signaling networks frequently altered in pancreatic cancer. Oncogenes exhibiting 
gain-of-function mutations are indicated by a dark dashed line. Tumor suppressor genes altered in the disease are 
indicated by a lighter dashed line. The frequencies at which these genes are altered are also included. Oncogenic KRAS 
mutation cooperates with the loss of various tumor suppressor genes to promote cellular proliferation, growth, survival, 
and stem cell renewal. B. Hippo signaling is frequently deregulated in pancreatic cancer. The ability of the pathway to 
restrict cell growth and induce apoptosis is mediated by a number of stimuli including cell density, glucose levels, 




Tumor suppressor genes 
 TSGs restrict cell proliferation in the presence of oncogenic driver mutations by 
inducing cell cycle arrest, apoptosis, or senescence. Hence, the functional inactivation of 
TSGs is essential for tumorigenesis [37]. A number of TSGs are functionally lost in 
PDAC, the three most common of which are CDKN2A, TP53, and SMAD4/DPC4 [6]. 
The inactivation of these genes occurs in a sequential manner following the appearance 
of oncogenic KRAS mutation in concordance with the multistage carcinogenesis model 
proposed by Vogelstein and colleagues (Fig. 1.1) [38]. Together, TSG alterations 
constitute a major driving force of PDAC development. 
 CDKN2A encodes the p16/INK4A protein, a cyclin-dependent kinase inhibitor 
responsible for blocking entry into S-phase of the cell cycle [39]. It is the earliest and 
most frequently altered TSG observed in PDAC. Approximately 95% of tumors exhibit 
functional loss of this gene as a consequence of intragenic mutation coupled with loss of 
the second allele (40%), homozygous deletion (40%), or promoter hypermethylation 
(15%) [40, 41]. CDKN2A inactivation is typically detected in moderately advanced 
PanINs, prior to the development of PDAC [42]. CDKN2A loss is crucial in disease 
pathogenesis, as p16 induces senescence following the introduction of oncogenic KRAS 
[43]. For this reason, CDKN2A inactivation occurs immediately following the 
appearance of activating KRAS mutations and at a similar frequency to bypass the 
senescence response. 
 The CDKN2A locus also encodes the tumor suppressor p14ARF, which is 




downstream exons shared with CDKN2A/p16 [39]. The p14ARF protein induces growth 
arrest or apoptosis by inhibiting MDM2-dependent p53 proteolysis. However, the 
frequent inactivation of p53 in PDAC, which often occurs concomitantly with p14 loss, 
suggests that this mechanism may not be relevant to disease progression. Furthermore, 
p14 inactivation only occurs as a consequence of CDKN2A deletion (40%) [40, 41]. 
Expression of this tumor suppressor is driven by an independent promoter that is 
unaffected by epigenetic changes influencing p16 transcription. Additionally, p14 
appears to be spared by p16-inactivating mutations. These discrepancies indicate that loss 
of p16 is more critical in disease pathogenesis and that p14 loss is a byproduct. However, 
p14 may hinder the development of PDAC via p53-independent mechanisms, as it has 
been shown to repress ribosomal RNA processing, NF-κB transactivation, and c-Myc-
induced hyperproliferation [44-46]. Furthermore, p14 can promote cell death by 
enhancing c-Myc-induced apoptosis as well proteasome-dependent degradation of the 
antiapoptotic transcriptional corepressor C-terminal binding proteins 1 and 2 (CtBP1/2) 
[46, 47]. Thus, p14 may hinder PDAC development via multiple mechanisms in specific 
contexts. 
 Another major TSG in PDAC is TP53, which encodes the transcription factor 
p53. Functional loss of this gene has been observed in up to 75% of tumors as a 
consequence of missense mutation and loss of heterozygosity (LOH) [40, 48]. Amino 
acid substitutions impair the ability of p53 to bind DNA, thus ablating its function as a 
transcription factor. As a consequence, mutant p53 is unable to induce the expression of 




PUMA) in response to cellular stress or DNA damage [49]. Inactivation of p53 is 
typically observed in advanced PanINs following the loss of CDKN2A [43]. At this stage 
of disease progression, the accumulation of DNA damage is believed to induce a 
selective pressure that necessitates the loss of p53 activity for the continued survival and 
proliferation of tumorigenic cells. 
 Emerging evidence suggests that TP53 mutations in PDAC may also contribute to 
the highly metastatic nature of the disease, thus defining a gain-of-function role for 
mutant p53 [50]. In one study, a specific tumor-associated mutant form of p53 
(p53R175H) was shown to bind the protein p73 and impair its ability to repress the 
expression of platelet-derived growth factor receptor β (PDGFRβ) [51]. The resulting 
upregulation of PDGFR expression promotes an autocrine signaling loop that enhances 
the motility, invasiveness, and metastatic potential of tumor cells in mice. Additional 
studies have demonstrated that inactivation of p53 in other cancer types also promotes 
metastasis by rendering the transcription factor incapable of inducing the expression of 
genes that counteract cell migration, epithelial-mesenchymal transition (EMT), and 
stemness [52, 53]. Thus, mutation of p53 may promote metastasis in PDAC via PDGFR-
independent mechanisms. Collectively, these studies highlight the complexity of genetic 
alterations in PDAC, as p53 functions as both a tumor suppressor and an enhancer of 
metastasis. 
 The low-frequency inactivation (<10%) of several additional TSGs has been 
observed in PDAC [54]. The most notable of these genes, STK11/LKB1, encodes a 




LKB1 as a consequence of germline mutation is most frequently associated with Peutz–
Jeghers syndrome (PJS), a disease characterized by the development of benign polyps in 
the gastrointestinal tract. Individuals with PJS have a 93% cumulative lifetime risk of 
developing other malignancies, the most frequent of which is PDAC (36% lifetime risk) 
[56]. As both germline and somatic/sporadic LKB1 mutations are found at low frequency 
in PDAC, LKB1 may play an important, context-specific role in disease pathogenesis 
[57]. One such context may be in the absence of p53 mutation, where LKB1 
haploinsufficiency was shown to cooperate with KRASG12D in a GEMM to accelerate 
PDAC development by suppressing p21-dependent cell cycle arrest [58]. This limited but 
critical role highlights the potential importance of low-frequency genetic alterations in 
subsets of PDAC. 
 Several caretaker genes, which have tumor suppressor function, are also 
functionally lost in subsets of PDAC. Unlike CDKN2A and TP53, which are considered 
classical TSGs, caretaker genes do not directly regulate proliferation. Rather, their 
function is to maintain the integrity of the genome, preventing the accumulation of 
mutations that might otherwise promote tumor development. A number of caretaker 
genes are lost in PDAC including BRCA1, BRCA2, hMLH1, and hMSH2 [6, 54]. 
Similar to LKB1, inactivation of these TSGs can occur as a consequence of germline or 
somatic mutation and is more commonly associated with other malignancies. However, 




The EGFR-KRAS network 
 Receptor tyrosine kinases (RTKs) are cell surface receptors for many growth 
factor ligands, including epidermal growth factor [59]. RTK dysregulation plays a 
significant role in many cancers. Upon binding to a growth factor ligand, RTKs form 
homo- or heterodimers, bringing their intracellular kinase domains into close proximity. 
The intracellular receptor regions are transphosphorylated to create docking sites for 
SH2-domain containing adapter proteins and enzymes. This activates many downstream 
signaling cascades mediated by proteins including RAS and PI3K (Fig. 1.2A) [60]. While 
EGFR mutations are rare in pancreatic cancer, inhibition of receptor kinase activity with 
erlotinib is moderately effective for treating a subset of PDACs [59]. Since KRAS is so 
frequently mutated in pancreatic cancer, the activation of RAS-mediated signaling 
pathways is thought to be a major driver of disease pathogenesis. Other RAS isoform 
genes such as HRAS and NRAS are mutated infrequently in pancreatic cancer, 
suggesting that the KRAS locus provides a unique advantage in the context of PDAC 
pathogenesis. Although not mutated in PDAC, HRAS and NRAS proteins may 
participate in EGFR/KRAS signaling networks to promote tumorigenesis via protection 
against DNA damage-induced stress pathways [61]. As discussed earlier, KRAS 
mutations occur early in PanIN lesions. Given the high prevalence of KRAS mutations, it 
is not surprising that the KRAS oncoprotein is a potent driver of PDAC development 
[62]. 
 RAS GAPs catalyze the hydrolysis of GTP to GDP, resulting in the inactivation 




suppressors, although they are not frequently mutated in PDAC. The GTP bound form of 
RAS undergoes a conformational change in which two “switch” regions (I and II) 
converge to form the effector-binding domain. This domain forms biochemical 
interactions with effectors to either promote their allosteric activation or enable 
recruitment to the membrane, allowing for initiation of downstream signal transduction 
cascades. One of the most well-studied classes of RAS effectors are RAF family S/T 
kinases, which initiate the MEK/ERK MAP kinase pathway through a cascade of 
sequential phosphorylation events [19]. This results in phosphorylation and nuclear 
localization of transcription factors, such as Elk-1, that drive cell proliferation, 
inflammatory signaling, differentiation, and cell survival. RAS can also activate the lipid 
kinase PI3K by associating with the p110 subunit of the PI3K complex. This complex is 
composed of a p110 catalytic subunit and a p85 regulatory subunit, which together 
regulate many key tumorigenic processes, including cell survival and proliferation. 
Activated RAS recruits PI3K to the plasma membrane and promotes its catalytic activity, 
which is to facilitate the conversion of the membrane phospholipid phosphatidylinositol-
4,5- bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 serves 
as a binding site for proteins that contain a pleckstrin homology domain. To inactivate the 
PI3K pathway, the lipid phosphatase PTEN hydrolyzes PIP3 to PIP2. PTEN is often 
dysregulated in late stages of pancreatic cancer resulting in hyperactivation of the PI3K 
pathway and an acceleration of PDAC development [63]. A primary effector of PI3K 
activation is the AKT S/T kinase, which is activated by sequential phosphorylation 




dependent p53 proteolysis. It can also activate mTORC1, which phosphorylates 4EBP1 
and ribosomal S6 kinase to promote CAP-dependent mRNA translation (Fig. 1.2A). The 
activation of mTORC1 is a key feature of many PDACs that results in increased protein 
translation, stem cell renewal, proliferation, and inhibition of autophagy via ULK1 kinase 
activation [64, 65]. 
Inflammation 
 Innate immune responses and inflammation have been associated with cancer 
etiology in many contexts, and pancreatic cancer is no exception. Recent studies using 
KRAS-driven GEMMs of PDAC have highlighted the role of acute pancreatitis-
associated inflammation in driving the progression of PanIN lesions to full-blown PDAC 
[66]. Some studies estimate that up to 50% of the PDAC tumor cell mass can be 
composed of stromal and immune cells recruited to the tumor via paracrine cytokine 
signaling [67]. Furthermore, oncogenic KRAS signaling can promote the development of 
the inflammatory microenvironment found in PDAC tumors. It is hypothesized that 
inflammation promotes PDAC initiation and progression through several different 
mechanisms. Firstly, it promotes cell survival and proliferation through inflammatory 
mediators that activate transcription factors responsible for antiapoptotic signaling as well 
as cancer cell invasion and metastasis. Examples of such proinflammatory, prosurvival 
transcription factors include STAT3, the AP-1 complex (Jun/Fos), and NF-κB. KRAS 
induces IL-6 and IL-11 cytokine expression and secretion, leading to STAT3 
transcriptional activation. KRAS also promotes NF-κB signaling via induction of the 




feedback loop for NF-κB activation. Reciprocally, NF-κB can enhance RAS activity 
through a RAS-NF-κB cyclooxygenase- 2 positive feedback loop [68]. Thus, 
inflammatory cytokines and RAS signaling are intimately linked. Secondly, 
proinflammatory cytokines, including TNFα, IL-6, and IL-1, can promote metastasis by 
inducing EMT as well as the acquisition of cancer stem cell (CSC)-like traits [67]. These 
mechanisms, coupled with the ability of NF-κB to activate Notch and other oncogenic 
pathways, lead to accelerated PDAC development. Finally, inflammation associated 
cytokines can impair immunosurveillance of tumor cells due to an increase in immune 
cell subsets that have immunosuppressive properties, including regulatory T-cells (T-
regs) and myeloid-derived suppressor cells (MDSCs).These cell types can negatively 
regulate the numbers and functional activation of cytotoxic CD8+ T-cells, possibly via 
increased expression of granulocyte–macrophage colony-stimulating factor (GM-CSF) 
[69, 70]. 
 There are likely to be a number of additional and diverse mechanisms by which 
inflammation promotes cancer. Inflammation can cause cellular damage, for example, via 
the accumulation of reactive oxygen species that promote oxidative DNA damage [67]. 
This may lead to increased genetic evolution in PDAC development as tumor cells 
acquire somatic mutations that confer selective advantages to promote growth and 
survival. When cells acquire an activating oncogenic mutation (e.g., KRAS), a 
phenomenon known as oncogene-induced senescence is triggered as a consequence of 
CDKN2A/p16 induction. This senescence response can be suppressed by inflammatory 




progression. Taken together, inflammation clearly plays a critical role in 
immunosuppression, KRAS pathway modulation, and cancer metastasis. Thus, targeting 
inflammatory pathways could represent an attractive avenue for therapeutic intervention. 
Deregulated EMT in pancreatic cancer 
 Epithelial cells are located at the surface of many tissues and organs that are 
derived from the endodermal and ectodermal embryonic germ layers. These cells form 
sheets that act as barriers against xenobiotic and pathogenic agents and serve specialized 
secretory functions in the intestine and the pancreas. Due to their location and function, 
epithelial cells exhibit a distinct apical–basolateral polarity created by macromolecular 
protein complexes at cell–cell contacts known as adherens and tight junctions. In contrast 
to epithelial cells, mesenchymal cells serve in anchoring or scaffolding roles and 
participate in early embryonic development, wound healing, and tissue repair. 
Mesenchymal cells lose apical–basolateral polarity as a consequence of the EMT 
transcriptional program. EMT is a developmental process in which the adherens and tight 
junctions of epithelial cells are degraded, resulting in a loss of cellular polarity and 
conversion to mesenchymal cells that are highly motile and invasive [71]. The key 
molecular changes associated with EMT are loss of epithelial protein marker expression, 
such as the adherens junction component E-cadherin, and gain of mesenchymal marker 
expression, including vimentin. During embryonic development, these cells can travel to 
distant sites and differentiate back into epithelial cells, known as mesenchymal-to-
epithelial transition, enabling tissue morphogenesis, tissue repair, and wound healing. 




cytokines, including TGF-β, Wnt, and Notch, resulting in the activation of signaling 
pathways such as NF-κB. Many of these factors and pathways are all commonly 
dysregulated in cancer [72]. Of note, cells within tumors displaying EMT properties have 
been identified using immunohistological methods. Many parallels can be drawn between 
the processes of wound healing and tumorigenesis, since both involve the recruitment of 
mesenchymal stem cells and are associated with increased cellular invasiveness. It is 
believed that EMT is an important step in cancer invasion and metastasis, as cells 
exhibiting EMT-like characteristics are often observed at the invasive front of tumors 
[73]. 
 EMT-associated signaling networks promote activation of the transcriptional 
repressors Snail, Slug, Zeb1, Zeb2/SIP1, and Twist [74]. These factors bind to the 
promoter of E-cadherin and block transcription by promoting chromatin condensation via 
the activation of histone deacetylases and other corepressors. This results in the loss of 
adherens junctions as well as loss of cell polarity [75]. TGF-β is a cytokine that promotes 
EMT through its ability to drive Smad complex association with Zeb proteins, resulting 
in repression of E-cadherin expression [76]. TGF-β-mediated induction of EMT is 
accompanied by apoptosis and growth arrest, known as lethal EMT. TGF-β can also 
induce transient activation of the RAS and PI3K/AKT pathways, which can help to block 
the apoptotic effects of the cytokine and produce a stable mesenchymal phenotype in 
cells [77]. Smad4, an important cofactor in TGF-β signal transduction, functions as a 




 In pancreatic cancer, as well as other malignancies, CSCs are multipotent or 
pluripotent progenitor cells in the tumor. CSCs can be identified and distinguished by 
high expression of cell surface markers including CD133 and CD44, which are typically 
not expressed on bulk tumor cells. They can self-renew as well as divide asymmetrically 
to give rise to differentiated cells. These characteristics allow CSCs to initiate or 
regenerate a tumor. CSCs are thought to be derived from existing progenitor cells or 
dedifferentiated cells within a tumor [75]. EMT is known to promote CSC-like properties 
in pancreatic cancer by inducing a CD44high and CD24low cell surface marker expression 
profile characteristic of CSCs [78]. This observation suggests EMT plays a direct causal 
role in the emergence of CSCs. However, the mechanistic basis for the association 
between EMT and CSC induction remains to be fully elucidated. 
 Mesenchymal-like properties can render pancreatic cancers more resistant to 
anticancer therapeutics, especially cytotoxic agents that induce apoptotic cell death. 
When comparing mesenchymal-like cells in pancreatic cancer to epithelial-like cells, 
mesenchymal-like cells are more resistant to gemcitabine, 5-fluorouracil (5-FU), 
cisplatin, and epidermal growth factor receptor (EGFR) inhibitors as assessed by cellular 
growth and viability [78]. Furthermore, pancreatic cancer cells that are intrinsically 
resistant to gemcitabine express high levels of vimentin and low levels of E-cadherin, 
indicating that these drug-resistant cells are more mesenchymal in nature [79]. As EMT 
has been associated with the emergence of CSCs, it has been noted that the use of 
cytotoxic agents such as gemcitabine can lead to an enrichment of CD44high, CD24low 




neoadjuvant radiotherapy, as resistant cells express high levels of vimentin and low levels 
of E-cadherin. These drug-resistant cells express high levels of the stem cell markers 
Oct4, CD24, and CD133, further indicating that EMT is associated with the acquisition of 
stem-like properties [80]. In the context of oncogenic KRAS signaling, studies indicate 
that loss of dependence on oncogenic KRAS for survival significantly correlates with 
mesenchymal-like phenotypic characteristics in PDAC cell lines [31]. These studies are 
supported by findings that primary PDAC tumors can be classified into distinct molecular 
subtypes based on the expression of EMT markers. These subtypes have been designated 
classical, exocrine-like, and quasimesenchymal. Of note, the cell lines with 
quasimesenchymal properties are weakly dependent on oncogenic KRAS to maintain 
viability [32]. 
 The clinical and pathophysiological significance of EMT in promoting metastasis 
and drug resistance remains controversial. A recent study has sought to tackle this 
question using EMT lineage tracing experiments in a spontaneous breast-to-lung 
metastasis model [81]. The study demonstrates that a small proportion of cells in primary 
tumors undergo EMT and that cells found in lung metastases are predominantly 
epithelial-like. Furthermore, blocking the EMT process via the overexpression of miR-
200, a negative regulator of Zeb1, does not significantly impair the formation of distant 
lung metastases. These findings strongly suggest that EMT is not necessary for metastasis 
to occur efficiently. Using the same experimental conditions, the study also demonstrates 
that treatment of primary tumors with the chemotherapeutic agent cyclophosphamide 




significantly to metastasis formation. Overexpression of miR-200 blocked this metastatic 
growth. Therefore, while EMT may not be required for metastasis under treatment naïve 
conditions, drug-resistant cells with EMT-like properties may emerge with an increased 
metastasis-forming ability. Such studies will be critical in addressing the key roles of 
EMT in driving cancer metastasis and drug resistance across a number of cancer types, 
including pancreatic cancer. Importantly, associations between the EMT program, the 
emergence of CSCs, cancer invasiveness, KRAS dependence, and drug resistance 
provide new therapeutic opportunities for pancreatic cancer treatment. 
Current and future therapeutic approaches 
 PDACs are notoriously difficult to treat for a number of reasons [9]. Most patients 
with PDAC are often asymptomatic, and diagnoses are not usually made until after the 
tumors have become metastatic. Currently, there are few effective therapeutic options for 
PDAC patients. The only “curative” treatment is surgical resection, but its success rate in 
patients with operable tumors is low, with a 5-year survival rate of only 20%, a 60% rate 
of relapse within 6 months, and an overall relapse rate of more than 80%. Due to the 
typically late diagnosis, many patients are not candidates for surgical resection. In 
contrast, chemotherapy has marginal, but measurable, effects on overall survival in 
PDAC patients. The efficacy of chemoradiation as a PDAC therapeutic regimen remains 
unclear when compared to chemotherapy alone. With current PDAC therapeutic options, 
overall survival of 5 years or greater is estimated to be less than 5%, and these rates have 
not changed significantly in the past 30 years. Understanding PDAC etiology and 




to treat the disease remains a pressing goal. PDAC is a complex disease with multiple 
stages that will respond to different sets of anticancer agents. The complexity of this 
disease is further highlighted by recent studies using a PDAC GEMM demonstrating that 
cells from PanIN lesions can metastasize. Pancreatic epithelial cells are able to 
disseminate from the pancreas at an early stage of the disease, when a primary lesion is 
not yet detectable. These cells are capable of seeding in the liver and potentially other 
distant sites. Therefore, therapeutics may be more successful if they are designed to treat 
pancreatic cancer as a systemic disease rather than localized one [82]. This could explain 
the low rate of success with local treatment, as cancer cells may be present at distal sites 
such as the liver or the lymph nodes. It is clear that new approaches to treat PDAC must 
be developed. A number of innovative avenues for therapeutic intervention are currently 
being evaluated in basic science and clinical studies [9]. 
 For PDAC patients with resectable lesions, the standard of care involves surgical 
resection and adjuvant chemotherapy with gemcitabine or 5-fluorouracil (5-FU). Both 
agents are pyrimidine analogs that block various stages of DNA replication, leading to 
cell cycle arrest and, in some cases, apoptosis. These conventional cytotoxic agents 
preferentially target rapidly dividing cells and can lead to the modest tumor regression or 
growth suppression. In metastatic disease, the standard of care is a drug regimen that 
consists of gemcitabine, FOLFIRINOX, or nab-paclitaxel. FOLFIRINOX is a 
combination chemotherapy made up of folinic acid (leucovorin), 5-FU, irinotecan, and 
oxaliplatin. These agents collectively interfere with DNA replication and transcription. 




disassembly and ultimately blocking progression through mitosis. Nab-paclitaxel is an 
albumin-bound form of the drug that has increased bioavailability. As these drugs 
indiscriminately target all rapidly dividing cells, many side effects and dose-limiting 
toxicities are associated with their utilization. For this reason, conventional cytotoxic 
chemotherapeutics provide only marginal increases in median patient survival on the 
order of weeks or months [9]. To improve the survival benefit conferred by these agents, 
many ongoing studies are investigating optimal dosing regimens and combinations for 
treating different stages of pancreatic cancer. Clinical trials involving chemoradiotherapy 
have returned inconsistent results, and the treatment remains controversial. This is 
possibly due to the lack of biomarkers to determine which patients will be responsive to 
radiation treatment. A newer strategy involves gemcitabine in combination with the 
EGFR tyrosine kinase inhibitor erlotinib, which results in a modest survival benefit of 12 
days compared to gemcitabine alone. Thus, erlotinib is the only FDA-approved targeted 
therapy available for treatment of pancreatic cancer. Some patients respond much more 
favorably to erlotinib than others, suggesting that there could be biomarkers to identify 
PDAC patients who will likely benefit most from anti-EGFR therapies such as erlotinib. 
A recent study found that TP53-wild-type tumors may be more sensitive to EGFR 
inhibition. Thus, identifying the right patient population for a particular targeted therapy, 
in the interests of precision medicine, remains a key goal of PDAC therapeutics [9]. 
 Effective targeted therapeutics and precision medicine-based approaches for 
PDAC have yet to be identified. One approach under investigation is to take advantage of 




is characteristic of pancreatic cancer, drug delivery to tumors is severely impaired. 
Hyaluronic acid is an extracellular matrix component found surrounding tumors that 
presents a physical barrier for drug delivery. The degradation of hyaluronic acid via 
hyaluronidase may enhance drug delivery. PEGPH20 is a PEGylated form of 
hyaluronidase that is currently being tested and shows prolonged survival of tumor-
bearing mice when given in combination with gemcitabine [83]. DNA-damaging agents 
such as TH-302 (evofosfamide) can take advantage of the hypoxic environment in 
pancreatic tumors to increase their specificity. This drug is derived from nitrogen mustard 
that becomes activated under hypoxic conditions and releases its active form, 
dibromoisophosphoramide mustard (Br-IDM), a DNA alkylating agent. In combination 
with gemcitabine, TH-302 provides a 6-month survival benefit compared to 3.6 months 
with gemcitabine alone [84, 85]. Drug modifications that provide improved delivery are 
also being evaluated, such as nab-paclitaxel or nanoliposomal formulations of irinotecan 
(MM-398). These modifications can increase the plasma half life of drugs and increase 
the availability of their active metabolites. MM-398 provides a 2-month survival 
advantage when given in combination with 5-FU and folinic acid [86]. To identify 
accurate biomarkers of response to particular agents, DNA sequencing of PDACs for 
sensitizing genetic alterations represents a major step in advancing precision medicines to 
treat the disease. Some examples currently under investigation include SMAD4 for 
chemoradiotherapy, STK11 for mTOR inhibitors, and the genes PALB2, ATM, and 




 Another avenue for therapeutic intervention could be to exploit oncogene 
“addiction” [87]. As mutant KRAS is a key linchpin in PDAC pathogenesis, it remains a 
major therapeutic target, albeit a stubborn one. Thus far, there has been little success in 
targeting the RAS-related proteins, due to their high affinity for GTP and the abundance 
of GTP in the cell, which prevent access to the protein active site. Nonetheless, many 
alternate methods of RAS inhibition are currently being investigated. The RAS protein 
must undergo several posttranslational modifications, including a farnesylation step, 
before the protein is functional. Blocking farnesylation of the protein is one potential 
method to inhibit the RAS pathway, but results have been disappointing thus far because 
KRAS can be alternatively isoprenylated with a geranylgeranyl group. After the RAS 
protein has been translated, it must be transported to the cell membrane, a process that 
requires the PDEδ protein. Thus, the PDEδ inhibitor Deltarasin has been developed, 
which can block RAS membrane translocation. This prevents the downstream activation 
of ERK, leading to suppression of KRAS-driven PDAC cell proliferation and viability. 
Although directly inhibiting KRAS has proven to be difficult, allosteric, covalent-
modifying inhibitors that stabilize the GDP-bound form of the protein have been 
identified for the G12C isoform commonly found in non-small-cell lung cancer 
(NSCLC). It is possible that a similar agent could be identified for the most common 
isoform found in pancreatic cancer, KRASG12D. As direct inhibition of KRAS remains a 
challenge, downstream inhibition of the RAF-MEK-ERK cascade and/or PI3K/mTOR 
has become an active area of investigation [9, 19]. Lastly, synthetic lethality is another 




promote PDAC tumor cell survival [87]. Thus far, genome-wide KRAS synthetic 
lethality siRNA screens have failed to yield promising candidate therapeutic targets, 
perhaps due to the complexity and molecular heterogeneity of oncogenic KRAS mutant 
PDAC tumors. 
 Altered cellular metabolism is yet another area being studied to develop PDAC 
therapeutics. In the tumor microenvironment, dense desmoplastic regions surround the 
tumor, leading to hypoxia and decreased nutrient delivery to cells. Tumors with increased 
glycolysis gain a survival advantage in the hypoxic environment (known as the Warburg 
effect), and autophagy is induced in response to nutrient deprivation. As described 
earlier, chloroquine, or its derivative hydroxychloroquine, inhibits autophagy by blocking 
the formation of autolysosomes. While chloroquine alone is mildly effective in promoting 
PDAC cell death, studies indicate that it can sensitize tumors to MEK inhibitors, 
chemoradiotherapy, gemcitabine, and nab-paclitaxel [88, 89]. 
 Finally, immunotherapy is an exciting field in cancer therapeutics that has 
demonstrated dramatic effects in other diseases, such as melanoma. This approach 
employs activation of the host immune system to combat tumors by promoting tumor cell 
clearance via cytotoxic T-cells. The immunosuppressive environment found in pancreatic 
cancer prevents immunosurveillance of tumors from occurring efficiently. Thus, 
supercharging the immune system to overcome this immunosuppression represents an 
innovative therapeutic strategy. One approach is to sensitize the immune system to 
pancreatic cancer cells through vaccination. GVAX pancreas is created from whole tumor 




cell division. These engineered pancreatic cancer cells are capable of recruiting dendritic 
cells that can phagocytose the tumor cells, which are subsequently presented to T-cells to 
promote their activation and ability to recognize and clear tumor cells [90]. Along the 
same lines, T-cells can be modified to express chimeric antigen receptors that recognize 
tumor antigens. This approach has been successfully achieved in CD19-positive 
hematological malignancies but is still in early development for pancreatic cancer [91]. 
CD40, a cell surface protein on antigen presenting cells plays a key role in immune cell 
activation. Thus, CD40 agonists are being tested in combination with gemcitabine to 
promote accumulation of phagocytic macrophages in tumors [92]. PD-L1 and PD-L2 are 
ligands expressed by cancer cells capable of binding to the immune checkpoint receptor 
PD-1 on activated CD8+ T-cells, causing suppression of cytotoxic T-cell function. This 
impairs immunosurveillance of cancer cells. Monoclonal antibodies that target PD-L1 or 
PD-1, such as pembrolizumab, have been developed to promote CD8+ T-cell activation. 
These agents have yielded significant beneficial results in melanoma, NSCLC, and renal 
cell carcinoma. As is the case with these malignancies, PD-L1 expression in pancreatic 
tumors is also associated with a poor prognosis [93]. Monoclonal antibodies against 
CTLA4 (e.g., ipilimumab), another T-cell immune checkpoint receptor, have also been 
tested in pancreatic cancer [94]. Unfortunately, checkpoint inhibitors have had 
disappointing results as single therapies in PDAC thus far. However, there is hope that 
they will be effective in combination with other chemotherapeutics, such as gemcitabine 
and nab-paclitaxel. In summary, PDAC remains one of the deadliest of all human 




for PDAC include optimizing the dosing regimens of current agents, targeting oncogene 
addiction, manipulating tumor metabolism, and harnessing the host immune system to 
fight this aggressive cancer type. 
Conclusions 
 PDAC is a highly aggressive malignancy associated with very poor clinical 
prognosis. Although the core genetic alterations in PDAC are well documented, their 
contributions to PDAC pathogenesis remain to be fully determined at the molecular level. 
Next-generation sequencing has revealed the detailed complexity of the genomic 
landscape of PDAC, which is characterized by marked inter- and intratumor 
heterogeneity as well as a very high overall mutational burden. Gene mutations in PDAC 
have been shown to converge on a few critical signal transduction pathways and cellular 
processes including the KRAS–MAPK pathway, inflammation, and altered cellular 
metabolism. The complexity of PDAC pathogenesis is further illustrated by the 
classification of PDAC tumors into four major molecular subtypes that are distinguished 
by key phenotypic traits and pharmacological vulnerabilities. Detailed characterization of 
these subtypes could ultimately lead to the development of new precision medicines for 
treating PDAC. However, current therapeutic options for the disease remain limited. 
Understanding and attacking the complexity of PDAC pathogenesis will undoubtedly 




The mTOR signaling pathway 
Overview 
 mTOR is a serine/threonine kinase that serves as a central hub that integrates 
metabolic and growth signals in the cell to regulate anabolic processes such as protein 
and lipid synthesis, as well as the catabolic process of autophagy. The kinase exists in 
two unique complexes. The nutrient and rapamycin sensitive mTOR complex 1 
(mTORC1) is composed of regulatory associated protein of mTOR (RAPTOR), mLST8 
(GβL), proline-rich AKT substrate 40 (PRAS40), and DEP domain containing mTOR 
interacting protein (DEPTOR). In this complex, RAPTOR directly activates mTOR 
kinase activity and recruits mTORC1 substrates [95, 96] while PRAS40 and DEPTOR 
serve as inhibitory subunits of mTOR [97, 98]. In contrast, mTOR complex 2 (mTORC2) 
is nutrient and rapamycin insensitive [99, 100] and composed of subunits mLST8, 
rapamycin-insensitive companion of mTOR (RICTOR), mSIN1 proteins, DEPTOR, and 
protein observed with RICTOR (PROTOR) [101-103]. Upstream mechanisms of 
mTORC2 activation are not fully understood. 
 mTORC1 integrates input from many different signaling pathways, primarily 
through the TSC1/2 complex (Fig. 1.3). The TSC1/2 complex resides upstream of 
mTORC1 and serves to negatively regulate mTORC1 through inactivation of the GTPase 
RHEB. In the TSC1/2 complex, TSC2 serves as a GAP for the GTPase RHEB, catalyzing 
the hydrolysis of GTP-bound RHEB to the inactive GDP-bound form [104]. RHEB can 
directly activate mTORC1 through an unknown mechanism [98]. Thus, the TSC1/2 




activators of mTORC1, can inactivate the TSC1/2 complex via the phosphorylation of 
TSC2 [105]. In addition, AKT is capable of phosphorylating PRAS40 on T246, releasing 
its inhibitory effects on mTOR [97, 106]. Interestingly, a major function of mTORC2 is 
to phosphorylate Akt at S473, a site required for maximal AKT kinase activity. AKT can 
then activate mTORC1 through the phosphorylation of TSC2 [107], placing mTOR both 
upstream and downstream of Akt activity. The TSC1/2 complex serves as a central hub 
of mTORC1 regulation because it can be regulated by several pathways sensing nutrient 
availability including AMPK, WNT-GSK3, hypoxia and glucocorticoids, allowing 
nutrient, oxygen, and energy levels to influence mTORC1 activity [108, 109]. Mitogenic 
signals also feed into mTORC1 through RAS-MAPK signaling via the direct 
phosphorylation and inhibition of TSC2 by ERK and p90-RSK [110].  
 These upstream inputs allow mTORC1 to act as a convergent hub that senses 
growth signals and the nutrient availability of the cell to regulate mRNA translation, lipid 
synthesis, and autophagy [111]. S6K1 and 4EBP are two substrates of mTORC1 that 
positively regulate CAP-dependent mRNA translation [112, 113]. The scaffolding protein 
eIF3 mediates mTORC1 phosphorylation of S6K1 and 4EBP by bringing the substrates 
into close proximity with mTOR. mTOR then activates S6K1 through phosphorylation on 
T389 [114], which can then go on to activate the translation initiation factor eIF4B and 
phosphorylate PDCD4 and targeting it for degradation. PDCD4 inhibits translation by 
inhibiting the helicase eIF4A, preventing the unwinding of RNA required for the 
translation machinery to be recruited [115]. 4EBP sequesters elongation initiation factor 




5’cap-dependent mRNA translation [116]. mTORC1 can also activate fatty acid and 
cholesterol synthesis by phosphorylating Lipin1 through an S6K1-dependent mechanism 
and releasing its inhibitory effect on the transcription factor SREBP [117], which 
activates genes responsible for fatty acid and cholesterol synthesis [118]. 
 During periods of anabolic protein and lipid synthesis, mTORC1 suppresses the 
process of autophagy, a major catabolic pathway that promotes protein and organelle 
degradation. mTOR is a potent negative regulator of autophagy through phosphorylation 
and negative regulation of key autophagy pathway activators, ULK1 and the MiT/TFE 
family of transcription factors. The ULK1 kinase forms a complex with ULK2, ATG13, 
FIP200, and ATG101 which is required for phagophore initiation. mTORC1 
phosphorylates ULK1, preventing its activation by AMPK and phagophore formation 
[119]. mTORC1 also phosphorylates the MiT/TFE family of transcription factors leading 
to 14-3-3 protein binding and cytoplasmic retention. This prevents the nuclear 
translocation of these transcription factors, thus preventing the activation of genes 





Figure 1.3. mTOR signaling regulates protein synthesis and autophagy. 
The mTOR kinase is a component of two signaling complexes. The mTORC1 complex integrates signals from 





Role in cancer development 
 mTORC1 serves as a central convergent hub of many common oncogenic 
pathways including the PI3K/Akt and Ras/MAPK pathways, and thus mTOR signaling is 
frequently deregulated in cancer. mTOR activation frequently occurs through Akt 
activation via PTEN deletion, PIK3CA activating mutations, BCR-ABL translocation, 
and amplification of HER2, EGFR, and AKT genes [123]. In addition, TP53 and LKB1, 
commonly lost tumor suppressors, are negative regulators of mTORC1 [124]. These 
mutations frequently result in mTORC1 hyperactivation. 
 Due to the central role of mTOR in tumor cell growth and proliferation, many 
inhibitors against mTOR have been developed and tested for cancer treatment. However, 
rapamycin and its first-generation analogs (rapalogs) have demonstrated limited 
therapeutic efficacy in clinical trials when used as single agents. Two rapalogs: 
temsirolimus and everolimus are approved for renal cell carcinoma, but have had only 
moderate success in the clinic [124]. Targeting mTOR in pancreatic cancer was shown to 
inhibit tumorigenesis, but phase 2 everolimus treatment of patients with gemcitabine-
refractory, metastatic pancreatic cancer had little clinical activity [125]. 
 Several possible reasons have been proposed for the lack of clinical efficacy with 
mTOR inhibitors. Rapalogs are allosteric mTORC1 inhibitors that do not equally block 
phosphorylation of all mTOR substrates. In particular 4EBP activity is largely resistant 
[126, 127]. mTORC1 inhibition also often results in a negative feedback loop resulting in 
the reactivation of PI3K-AKT signaling and increased signaling in this pathway [128, 




many cancers are able to escape rapamycin/rapalog treatment. To overcome this, 
inhibition of multiple components of the mTOR signaling pathway appears to be a more 
effective approach and has been tested with more robust mTOR kinase inhibition and cell 
killing in pancreatic cancer [130]. Alternately, mTOR inhibition leads to autophagy 
activation, which can support cancer cell survival when the cells are subject to nutrient 
starved conditions [131]. Some have proposed that this may serve as a mechanism to 
evade apoptosis when mTOR is inhibited. Combination mTOR and autophagy inhibitor 
treatment, with temsirolimus and hydroxycholroquine, was tested in a phase 1 clinical 
trial in metastatic melanoma that showed improvement over temsirolimus alone [132]. 
 Given the variability in the efficacy of mTOR inhibitors in clinical trials, it is 
becoming more crucial that we identify biomarkers for mTOR inhibitor sensitivity. Even 
so, mTOR inhibition as a single therapy may never be an effective therapeutic approach. 
The role of mTOR in protein synthesis and growth is critical to most human tissues, 
leading to adverse toxicity that limits the dose that can be administered. Identifying tissue 
specific mechanisms of mTOR inhibition, as well asfurther characterization of the mTOR 
pathway and the determinants of pathway sensitivity may uncover more effective 
combinations of therapeutics. 
Homeostatic regulation of the autophagy pathway 
Overview 
 Autophagy is a well-characterized metabolic, homeostatic process by which 
cellular constituents, such as proteins and organelles, are degraded and recycled to meet 




during tumorigenesis, and indeed, constitutive activation of autophagy has been observed 
in many tumor types including PDAC [133, 134]. Three types of autophagy are typically 
described: macroautophagy, microautophagy, and chaperonin-mediated autophagy. 
Macroautophagy, henceforth referred to simply as autophagy, is the primary pathway, as 
well as the most significant in PDAC. During nutrient deprivation, misfolded and 
nonessential proteins, as well as organelles, are sequestered into a lipid bilayer known as 
a phagophore. The phagophore matures to give rise to a double-membraned structure 
known as the autophagosome, which subsequently fuses with a lysosome, forming an 
autophagolysosome or autolysosome. Degradative enzymes combined with low pH 
within autolysosomes cause the breakdown of cellular macromolecules. Amino acids and 
other building blocks are then recycled, allowing for cellular homeostasis to be 
maintained. In normal pancreatic tissue, there is a basal level of autophagy that serves to 
maintain homeostasis [133]. 
Role in cancer development 
 The role of autophagy in pancreatic cancer is complicated and has yet to be fully 
elucidated. Numerous studies have suggested that autophagy prevents cancer progression 
in pre-malignant lesions. In more advanced cancers, autophagy can be utilized as a 
mechanism to sustain tumor cell survival and growth [135]. Even so, published findings 
have shown that activating or inhibiting autophagy are both potential therapeutic 
approaches in advanced cancers [136, 137], though the majority have focused on 
autophagy inhibition. It is also possible that a homeostatic balance of autophagy pathway 




balance may cause destabilization of cell metabolism leading to defects in cell growth 
and survival. Our understanding of the role of autophagy in cancer progression is 
incomplete and further study is needed into the contexts and mechanisms by which 
autophagy can be oncogenic or tumor suppressive. 
 Autophagy is universally activated in PDAC, as indicated by increased number 
and size of both autophagosomes and autolysosomes, when compared to normal 
pancreatic tissue [138]. It is hypothesized that tumor cells gain a selective advantage 
when autophagy is activated, as it may allow them to cope with cellular and metabolic 
stress due to increased cell division under conditions of nutrient and oxygen deprivation 
in poorly vascularized regions of the tumor [139]. Therefore, autophagy can drive the 
survival of PDAC cells under these conditions, by promoting the recycling of cellular 
macromolecules. 
 A primary mechanism that controls autophagy pathway activation in PDAC is via 
upregulation of the MiT/TFE family of transcription factors. These transcription factors 
control the expression of genes important for lysosome biogenesis and autophagy, 
including ATG10, ULK2, MAP1LC3A, and SQSTM1 [138]. Chloroquine, which inhibits 
autophagy by blocking the formation of autolysosomes, potently suppresses the growth of 
some PDAC cell lines. When autophagy is inhibited with chloroquine, or by genetic 
ablation of the key autophagy regulator Atg-7, Kras-induced progression of PanIN to 
PDAC is blocked as a consequence of cell death, growth arrest, or senescence [140]. 
However, when combined with TP53 deletion, Atg-7 loss enhances, rather than 




context-dependent role of autophagy in PDAC pathogenesis, which depends on TP53 
status and possibly other TSG mutations. Lastly, autophagy could allow PDAC cells to 
cope with the deleterious effects of chemotherapeutics and radiation therapy. For 
example, treatment of the PDAC cell line PANC-1 with gemcitabine or 5-fluorouracil 
induces autophagy [139]. Interestingly, the combination of autophagy inhibitors, such as 
chloroquine, with chemotherapy or radiation therapy greatly enhances cytotoxicity in 
PDAC cell lines. Furthermore, recent studies have suggested that pancreatic cancer cells, 
in response to MEK and ERK inhibition, may upregulate autophagy as a “resistance” 
mechanism, permitting cells to escape the loss of mitogenic signals by activating the 
catabolic pathway as a means to bypass the loss of growth stimulation. In these studies, 
combining MEK/ERK inhibition with autophagy blockade resulted in an enhanced 
antiproliferative effect in PDAC cell lines [142-145]. 
The spleen tyrosine kinase signaling pathway 
Overview 
 Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase highly expressed 
in cells of the hematopoietic lineage, and known to have essential functions in immune 
receptor signaling [146]. It is well known that B-cell and T-cell receptor ligand binding 
results in the activation of SYK, which can then activate several downstream pathways 
that participate in lymphocyte differentiation, growth, and proliferation among many 
other functions. Due to its crucial role in the immune system, countless studies have 




therapeutic target in related pathologies including autoimmunity, allergy, inflammation 
and in hematopoietic cancers. 
 Initially, it was presumed that SYK expression was limited to cells of the 
hematopoietic lineage. Indeed, the best characterized role of SYK is in immunoreceptor 
signaling. However, more recent studies have revealed that SYK is expressed in a wide 
variety of cell types, including epithelial cells and even adipocytes [147], and can 
participate in non-immunoreceptor signaling, for example via integrins and lectins [148-
150]. We identified SYK as positively correlated with KRAS-dependency in KRAS-
mutant pancreatic, colon, and lung cancer cell lines. This has led to further interest in 
understanding the mechanisms of SYK kinase signaling and as a potential therapeutic 
target for cancers of epithelial origin. This section will provide details on the structure 
and function of SYK as well as SYK-dependent signaling pathways. This information is 
being leveraged to explore SYK as a potential therapeutic target for the treatment of 
several disorders.  
Structure and function 
 The full-length isoform of SYK (SYK-A) is a 72 kDa protein composed of two 
SRC homology 2 (SH2) domains at the N-terminus connected by a linker region known 
as interdomain A. At the C-terminus is the kinase domain, connected to the SH2 region 
by interdomain B (Fig. 1.4). A splice variant of SYK (SYK-B) is truncated compared to 
SYK-A due to the loss of a 23 amino acid sequence in interdomain B. This sequence 
contains a nuclear localization signal, but its loss does not affect SYK kinase activity 




phosphorylation sites that serve important regulatory roles controlling the protein 
conformation as well as effector binding of SYK. These phosphorylation sites are 
described below for the human SYK protein with the corresponding mouse protein sites 
in parentheses. 
 When SYK is inactive, the protein adopts an inactive closed conformation 
through interactions between interdomains A and B with the kinase domain. Disruption 
of these inhibitory interactions either through SH2-ITAM binding or direct 
phosphorylation of the linker regions causes a conformational rearrangement, activating 
the catalytic kinase domain of SYK [151]. B-cell receptor (BCR) activation has been 
shown to cause the phosphorylation of four sites on SYK, resulting in destabilization of 
the inhibited conformation [152]. The tyrosines Y348 and Y352 (Y342 and Y346 in 
mice) reside in interdomain B and Y630 and Y631 (Y624 and Y625 in mice) reside in the 
kinase domain. Lyn, a Src family kinase, is capable of phosphorylating these sites to 
activate SYK [153]. These tyrosine sites participate in stabilization of the inhibited 
conformation of SYK and mutation of these four sites results in constitutive kinase 
activation [154, 155]. These sites are also thought to participate in binding of proteins 
involved in downstream signaling [156]. Disruption of the inhibited conformation via the 
deletion of the interdomain A has also been shown to activate SYK [157]. The tyrosine 
sites Y525 and Y526 (Y519 and Y520 in mice) are located in the SYK activation loop of 
the catalytic domain and required for SYK function. These sites are phosphorylated after 
BCR activation binding as well as autophosphorylated by SYK [158]. Phosphorylation at 




suggesting that autophosphorylation is the primary mechanism of phosphorylation at 
these sites. Another study suggests that initial phosphorylation at Y525/526 and 
activation of SYK is mediated by Src-family kinases such as Lyn, followed by SYK 
kinase-dependent autophosphorylation [160]. 
 Tyrosine phosphorylation of Y323 (Y317 in mice) results in a negative regulatory 
effect, inhibiting the catalytic domain of SYK [159]. Phosphorylation at this site also 
results in increased binding of Casitas B-lineage lymphoma (c-CBL), an E3 ubiquitin 
ligase, leading to the degradation of SYK [161]. Along with the negative regulatory role 
of Y323, this phosphorylation site can also directly bind to p85α, a regulatory subunit of 
PI3K, along with Y348 and Y352 (Y342 and Y346 in mice) aiding in the activation of 
PI3K [162]. Other tyrosine phosphorylation sites that bind SYK effectors include the two 
tyrosine sites Y348 and Y352 which bine and activate VAV1, a guanine nucleotide 
exchange factor (GEF) for Rho family GTPases, and phospholipase C gamma 1 (PLCγ1) 
[163, 164]. SLP65 binds phosphorylated Y630 (Y624 in mice), which is important for 
BCR signaling and B-cell development [165]. 
 The mechanisms controlling dephosphorylation of SYK are not fully understood, 
although it has been proposed that phosphatases such as SH2 domain-containing protein 
tyrosine phosphatase 1 (SHP-1), protein tyrosine phosphatase receptor type O truncated 
(PTPROt), and phosphoenolpyruvate phosphatase (PEP) inactivate SYK signaling 
through direct dephosphorylation of tyrosine residues as well as dephosphorylation of 




 The structure of another closely related protein, ζ-chain-associated protein kinase 
70 (ZAP-70), is similar to SYK in that it also has two SH2 domains and a kinase domain 
connected by two linker regions. Like SYK, its two SH2 domains can bind 
phosphorylated ITAMs of an activated T-cell receptor complex. Due to the resemblance 
in structure to SYK, the linker region of ZAP-70 similarly contains tyrosine sites which 
can be phosphorylated to promote binding of many of the same downstream binding 
partners as SYK, such as PLCγ and CBL, allowing it to function as an adaptor molecule 
in a manner akin to SYK. Src family kinases phosphorylate ITAMs which can then 
recruit either SYK or ZAP-70 to bind via their SH2 domains, but, interestingly, Zap-70 is 
more dependent on Src family kinases for activation, likely due to its inability to 
phosphorylate the ITAM tyrosine residues itself [169]. 
 
Figure 1.4. The structure of SYK. 
A stick diagram of the structure of SYK, consisting of two SH2 domains and a catalytic kinase domain. Important 





Upstream receptor-mediated activation of SYK  
 SYK is activated via several mechanisms. The best documented of these 
mechanisms depends on the dual phosphorylation of tyrosine residues on membrane 
bound immunoreceptor tyrosine-based activation motifs (ITAM) by Src family kinases. 
These ITAM motifs are found in either membrane bound adaptors that form complexes 
with activated receptors, as in the case of B cell and T cell receptors. ITAM motifs are 
also found in the intracellular tail of the receptors themselves, as in the case of the 
FcγRIIA receptor. Dual phosphorylation of these ITAM motifs provides a site for the 
SH2 domains of SYK to bind. Each phosphorylation site binds to one SH2 domain, thus 
destabilizing the inhibited conformation of SYK (Fig. 1.5). This binding and 
conformational change rapidly activates the catalytic domain of SYK and allows for the 
phosphorylation of downstream substrates [149]. More recently, the lectin receptors 
CLEC2, CLEC7A, and CLEC9A, involved in recognition of bacteria, fungi, and tissue 
damage, have been shown to contain hemITAMs in their intracellular tail. In this case, 
two ligand bound receptors must form a duplex, bringing the phosphorylated hemITAM 
motifs in close enough proximity to each other that the SH2 domains of a single SYK 
protein can bind to both. In the development of pancreatic cancer, chronic pancreatitis is 
a common risk factor that results in extensive tissue damage [170]. Lectin receptors could 
potentially activate SYK in these cells resulting in increased mitogenic signaling and 
promoting tumorigenesis. SYK, unlike ZAP-70, is also capable of independently 
phosphorylating these ITAM tyrosine residues leading to self-activation, forming a 




 In the absence of ITAM motif phosphorylation, SYK is known to be activated 
through several alternate mechanisms. Src family kinases, such as Lyn, can directly 
phosphorylate tyrosine residues on the SYK linker region to activate the catalytic domain 
without the need for ITAM binding [153, 172]. In epithelial cells, such as those in the 
pancreas, ITAM motifs are not a primary mechanism of receptor signal transduction and 
it is possible that ITAM independent activation of SYK via Src family kinases could play 
a role in these cells. SYK can also be activated through the binding of its SH2 domains to 
cytoplasmic tail of αIIbβ3 integrin [173]. Lastly, activated SYK is capable of 
autophosphorylation [152]. It is thought that receptor activation of SYK provides rapid 
and transient activation of the kinase, and the ability to autophosphorylate is important 





Figure 1.5. SYK activation through the phosphorylation of ITAM motifs 
Src family kinases such as LYN phosphorylate intracellular ITAM motifs. The SH2 domains of SYK bind these 





Regulation of downstream signaling pathways by SYK 
 Once activated, SYK binds to and recruits a number of SH2-domain containing 
proteins, such as PLCγ, the regulatory p85α subunit of PI3K, and SH2 domain-containing 
leukocyte protein (SLP) family proteins. The net effect is activation of downstream 
mitogenic pathways such as the PKC, RHO, PI3K-AKT and RAS-ERK pathways [149]. 
Constitutive SYK expression can activate RAS-ERK signaling, though the mechanisms 
are not clearly defined. In one study, the 5’ moiety of TEL was fused to SYK resulting in 
constitutive SYK kinase activation. This caused constitutive activatation of RAS in the 
murine hematopoietic cell line BaF3, but this study did not determine the mechanism for 
MAPK activation [174]. In another study, Zymosan, a ligand found on the surface of 
fungi, induced SYK-dependent ERK activation in bone marrow derived cells [175]. A 
potential mechanism for ERK activation was found through crosslinking of BCR in the 
lymphoblast cell line DT40, which resulted in SYK activation and rapid phosphorylation 
of RAS-GAP. SYK deficiency in these cells ablates tyrosine phosphorylation of RAS-
GAP. These researchers did not further determine if this RAS-GAP phosphorylation had 
any effect on the activity of RAS-GAP or RAS [176]. One potential mechanism was 
detailed in a study which found that SYK phosphorylates PKC upon FcεRI stimulation in 
mast cells, which generates SH2 binding sites for the recruitment of the Grb-2-Sos 
complex to activate Ras [177]. 
 SYK can also activate NF-κB-dependent chemokine and cytokine expression, in 
particular IL-2, IL-10, and IL-23, increasing TH17 response [178]. Activation of NF-κB 




fully understood [179]. In response to fungal antigen binding, IL-1β is processed from 
pro-IL-1β by the NLRP3 inflammasome, activated by SYK-dependent ROS production. 
SYK also regulates pro-IL-1β production, in dendritic cells to activate anti-fungal 
response [180]. Interestingly, even though SYK is primarily a tyrosine kinase, there is 
evidence that SYK may be able to phosphorylate serine residues on certain substrates 
such as the transcription factor Ikaros [181] and CD79a [182]. 
 Recent studies have shown that SYK regulates mTOR signaling. In brown 
adipose tissue, SYK was found to be required for pre-adipocyte proliferation and 
differentiation through the activation of the mTOR pathway [183]. SYK regulation has 
been linked to mTOR in AML [184] and follicular lymphoma [185, 186]. We have also 
found a link between SYK activity and mTORC1 activation in KRAS-mutant pancreatic 
cancer cell lines. Interestingly, this regulation of mTOR does not appear to be linked to 
MAPK or PI3K/Akt activation and its mechanism of action is currently unknown. 
 Beyond hematopoietic cells, SYK is expressed in a wide variety of other cell 
types and tissues [147]. Fibroblasts require SYK for adipogenesis [187] and brown fat 
differentiation [183]. SYK has been shown to be expressed in normal and malignant 
breast tissue [188], as well as pancreas tissue [189]. Normal hepatocytes activate SYK in 
response to angiotensin II [190] and SYK is frequently silenced in hepatocellular 
carcinoma [191]. SYK may even be involved in neuronal cell differentiation [192]. 
Regulation of lymphocyte function 
 The role of SYK in B-cell and T-cell receptor signaling makes it essential in 




tyrosine residues on an intracellular ITAM adapter are phosphorylated, creating binding 
sites for the SH2 domains in SYK. Upon binding to the phosphorylated ITAM motif, the 
catalytic domain of SYK is activated. In T-cells, SYK is primarily involved in early T-
cell development, where it participates in pre-T-cell signaling. SYK-deficient mice are 
impaired in pre-TCR signaling during beta selection [193]. In B-cells, SYK plays a much 
more significant role. B-cells are completely absent in SYK deficient mice [194]. This is 
because SYK is expressed throughout B-cell development and participates in several of 
the steps of B-cell development. SYK is important in the maturation of pro-B-cells to 
pre-B-cells and is essential in the RAC-dependent checkpoint that allows them to enter 
the splenic white pulp [195]. SYK is also required for leukocyte adhesion during 
inflammation [196]. SYK deficient neutrophils have defects in integrin mediated rolling 
[197] and integrin mediated signaling is defective in SYK deficient neutrophils and 
macrophages [148, 150]. 
SYK-dependent control of inflammation and autoimmune disease 
 The broad importance of SYK in immune cell signaling has led to extensive study 
of the kinase in the context of immune system dysfunction. For instance, asthma and 
allergic rhinitis are closely related by overactive neutrophil, mast cell, and macrophage 
response to often benign antigen exposure. SYK is involved in FcεRI signaling and the 
degranulation of mast cells [198] and FcγR signaling in neutrophils, macrophages [199], 
and NK cells [200]. Mast cells in SYK deficient mice fail to degranulate and release 
histamine [198]. Dendritic cells encounter allergens that are presented to CD4+ T-cells, 




production of IgE that binds to the mast cell receptor FcεRI [201]. This IgE-FcεRI 
complex can then bind an allergen, activating the phosphorylation of ITAM tyrosine 
residues by Lyn, a Src family kinase, and the recruitment and activation of SYK [202]. 
SYK can then phosphorylate downstream adapters such as LAT and SLP-76, causing 
inflammatory mediator release. Activation of PKC and ERK causes leukotriene and 
prostaglandin production [146]. Due to the critical role of mast cells in the pathology of 
asthma [203], SYK could be an effective target to prevent mast cell degranulation in 
asthmatic patients and a clinical trial showed that intranasal administration of a SYK 
inhibitor could be used to treat allergic rhinitis [204]. 
 Rheumatoid arthritis is another disease mediated by hyperactivation of 
inflammatory processes resulting in damage to joints in the body [205]. Circulating IgG 
binds self-antigen, which is recognized by innate immune cells such as macrophages 
through Fcγ receptors. This, in turn, activates SYK through ITAM based recruitment 
[206]. The IgG-antigen complexes are then phagocytosed, leading to the generation of 
reactive oxygen species (ROS) and nitric oxide (NO) that can lead to tissue damage. It 
has been shown that SYK-deleted macrophages and neutrophils do not phagocytose these 
particles or generate ROS and NO in response [199, 207]. Furthermore, SYK deletion 
blocks joint inflammation [208], and SYK siRNA injected into joints decreases 
inflammation and swelling in a rheumatoid arthritis mouse model [209]. Tests using a 
SYK inhibitor reduces rheumatoid arthritis related inflammation in a manner consistent 




 Autoimmune disorders extend far beyond rheumatoid arthritis. SYK inhibition 
has been effective in mouse models of systemic lupus erythematosus [211, 212], type I 
diabetes [213], and several autoimmune driven thrombocytopenias, where self-reactive 
antibodies against platelets causes activation and clotting disorders [214, 215]. Due to the 
important role of SYK in activating growth, proliferation, and cytokine production in 
inflammatory and immune responses, SYK may be a lucrative target in disorders 
involving overactive immune response such as allergic or inflammatory responses and 
autoimmune disorders. Inflammation of the pancreas is an important risk factor in the 
development of pancreatic cancer. This inflammation is thought to occur early during 
oncogenesis as a result of initial genetic mutations in cooperation with oncogenic KRAS 
[216]. Inhibition of SYK could be an effective therapeutic approach in these contexts. 
Oncogenic and tumor suppressive roles of SYK in cancer 
 Numerous studies have investigated the role of SYK in various cancer types, 
indicating an important role for the kinase in this context. Evidence thus far appears to 
suggest that the role of SYK in cancer is complex, with often seemingly conflicting 
findings. SYK expression and activity is often altered in cancer. Genetic mutation or 
deletion of SYK is uncommon, though it has been reported [217], and loss of SYK 
expression appears to occur primarily through epigenetic silencing as a result of 
hypermethylation of its promoter [188, 191, 218]. The loss of its nuclear localization 
signal occurs through alternative splicing [219]. 
 Due to the role of SYK in activating lymphocyte proliferation, SYK has 




leukemias or lymphomas. SYK inhibition in chemotherapy-resistant primary B-cell acute 
lymphoblastic leukemia (ALL) resulted in apoptosis of the B-cell precursor leukemia 
cells [220]. Some B-cell lymphomas exploit ITAM mediated signaling for cell survival 
leading to constitutively active SYK [221, 222]. In chronic lymphocytic leukemia (CLL), 
expression of the antiapoptotic factor myeloid cell leukemia sequence 1 (Mcl-1) 
increased with SYK activation due to PKCδ and PI3K/Akt pathway activation [223]. 
Inhibition of SYK in this context resulted in apoptosis [224, 225]. SYK activation of Akt 
was found to block phosphorylation of Mcl-1 resulting in ubiquitination and proteasomal 
degradation. 
 The majority of diffuse large B-cell lymphomas (DLBCL) exhibit tonic BCR 
signaling that is dependent on SYK. SYK inhibition with the kinase inhibitor R406 
induced apoptosis in these cells [226]. Furthermore, in DLBCL, SYK represses 
expression of the pro-apoptotic protein Harakiri (HRK) [227]. In mantle cell lymphoma, 
among the B-cell lymphomas with the worst prognosis, SYK was found to be amplified 
and inhibition with piceatannol resulted in cell proliferation arrest and apoptosis [228]. 
The same trends are found in non-Hodgkin lymphoma [229], Epstein Barr virus B-cell 
lymphomas [230], and even include some T-cell malignancies. For instance, studies 
found that peripheral T-cell lymphomas had overexpression of SYK [231] and that SYK 
was identified in a proteomic screen as a potential target for acute myeloid leukemia 





 As previously discussed, SYK function is not limited to cells of the immune 
system and is found in a wide variety of tissue types including epithelial cells of the 
pancreatic duct. SYK has been studied in several different tumor types, but its role is not 
as well-defined as in hematopoietic cancers. In breast cancer, one study found that SYK 
activity is correlated with decreased invasiveness of breast cancer cell lines and improved 
survival outcomes of breast cancer patients. Blockade of SYK activation promoted 
tumorigenesis [233]. Another group of researchers added that loss of SYK expression is 
associated with increased invasiveness and that this was specifically due the loss of 
nuclear localized SYK. Expression of the truncated isoform SYK-B lacking a nuclear 
localization signal was also associated with increased invasiveness. Expression of SYK-
A resulted in nuclear localization and suppressed invasiveness in breast cancer [219]. In 
contrast, one study found that SYK promotes tumor malignancy, increasing cell survival, 
proliferation, and tumor aggressiveness, and that this was specific to the full-length SYK-
A isoform [234]. SYK is expressed in >40% of gastric cancers and survival was found to 
be higher with decreased lymph node metastasis with increased nuclear SYK expression 
[235]. In pancreatic cancer, SYK slows cell growth and invasiveness [189], and SYK 
knockdown caused apoptosis in pancreatic and lung cancer cell lines [31]. In melanoma, 
SYK is epigenetically silenced [218], and when re-expressed, induces cell senescence 
[236]. 
Association of SYK expression with KRAS dependence 
 A transcriptional signature for KRAS dependence found that SYK expression was 




[31]. This study also found that the KRAS-dependent cells were more epithelial-like than 
the more mesenchymal-like KRAS-independent cell lines. SYK depletion in KRAS-
dependent lung and pancreatic cancer cell lines caused loss of E-cadherin expression, 
implicating a possible role for SYK in epithelial-mesenchymal transition (EMT) [31]. 
EMT is thought to be important in the metastasis and invasiveness of cancer due to its 
ability to generate cancer stem cells (CSC) [75]. As previously discussed, there are 
several documented studies that support the idea that SYK is involved in the invasiveness 
of solid tumors including breast, gastric, and pancreatic cancer. In breast cancer, SYK 
expression promoted the formation of cell-cell contacts and the distribution of adhesion 
proteins cortactin and vinculin to these sites, which are required for E-cadherin-mediated 
contact formation [237]. Another study found that SYK is localized to cell-cell contacts. 
They utilized phosphoproteomics to identify SYK mediated phosphorylation of E-
cadherin and α-catenin which was important for the localization of p120-catenin at 
adherens junctions [238]. 
SYK as a therapeutic target in inflammation and cancer 
 Several small molecule SYK kinase inhibitors have been developed and tested. 
Fostamatinib (R788, Rigel) and its active metabolite R406 are widely used, but not very 
specific ATP-competitive SYK inhibitors [239, 240]. Fostamatinib decreased joint 
inflammation in Phase II clinical trials [241, 242], but the inhibitor had adverse effects 
and a lack of efficacy in RA patients with resistant disease. Phase 1 and 2 clinical trials in 
non-Hodgkin lymphoma and CLL show decreased expression of BCR target genes [225, 




thrombocytopenia (ITP) found that SYK inhibition provided meaningful clinical 
improvement of ITP patients [244]. The combination of the SYK inhibitor GS9973 with 
PI3K inhibitor idelalisib had additive effects on growth inhibition [245]. PRT062607 is a 
more recent ATP-competitive small molecule SYK inhibitor and highly specific [210]. 
Combination of the SYK inhibitor PRT062607 with the purine nucleoside analog 
fludarabine caused synergistic growth inhibition in non-Hodgkin lymphoma and CLL in 
mouse xenografts [246]. A combination SYK, JAK1, JAK3, and TYK2 inhibitor 
cerdulatinib had good efficacy in the treatment of B- and T-cell non-Hodgkin lymphoma 
in a phase 2 clinical trial [247]. 
 The role of SYK in promoting lymphocyte proliferation and activation has made 
it the subject of several clinical trials for the treatment of hematopoietic cancers and 
autoimmune diseases. More recent findings that SYK is expressed and activates 
mitogenic signaling in diverse tissue types has led to further investigation of SYK as a 
potential therapeutic target in solid tumors. SYK inhibition may not only suppress 
mitogenic signaling in tumor cells, but it may also target the inflammatory 
microenvironment associated with pancreatic and many other types of cancer. Given the 
myriad function of SYK, there are concerns that systemic SYK inhibition could result in 
unintended adverse effects, such as the suppression of the immune system. More 
extensive in vivo studies are needed to determine the effects of systemic administration 





 Our knowledge of SYK function has grown from its crucial role as a kinase in 
lymphocyte immunoreceptor function to a broader role in a vast array of tissue types 
including other immune cells and organs. Moreover, SYK has been demonstrated to have 
important functions in autoimmune disease and the oncogenesis of hematopoietically 
derived cancers as well as solid tumors. Inhibitor studies have indicated that SYK could 
be an effective target for therapeutics in many of these disorders and the development and 
study of new and more specific SYK inhibitors will be an important path forward in 




CHAPTER TWO: THE SYK TYROSINE KINASE SUPPRESSES 
AUTOLYSOSOME BIOGENESIS VIA ACTIVATION OF MTORC1 IN 
PANCREATIC CANCER CELL LINES 
Abstract 
 Spleen tyrosine kinase (SYK) regulates mitogenic signaling, inflammatory 
responses and cell fate in a variety of tissue lineages. We previously showed that SYK is 
expressed in a subset of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) cell 
lines. In this study, we demonstrated that SYK kinase inhibition with PRT062607 (SYKi) 
causes decreased cell proliferation of PDAC cell lines. Furthermore, combined inhibition 
of SYK and the KRAS effector kinase MEK causes additive suppression of PDAC cell 
proliferation. Mechanistically, SYKi treatment causes reduced phosphorylation of 
ribosomal S6 protein and its upstream kinase p70 S6 kinase in PDAC cell lines, 
indicating that SYK activates the mTORC1 kinase complex. SYK-mediated mTORC1 
activation occurs independently of MEK/ERK and PI3K/AKT effector signaling 
pathways. The mTORC1 complex suppresses lysosome biogenesis and macroautophagy 
(autophagy). Consequently, mTORC1 suppression via SYK inhibition or shRNA-
mediated depletion causes accumulation of autolysosomes. These effects are mediated by 
the enhanced nuclear localization of MITF, a key transcriptional regulator of genes 
involved in lysosome biogenesis and autophagy pathway activation. In summary, SYK 
positively regulates mTORC1 activation in a subset of PDAC cell lines to suppress 




SYK as a critical regulator of mTORC1 and autolysosome biogenesis in PDAC, and how 
this pathway may be exploited for therapeutic benefit. 
 Implications: This study shows that SYK activates mTORC1 to suppress 
autophagy pathway activation in pancreatic cancer cells, representing a potential 
vulnerability for therapeutic intervention. 
Introduction 
 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer of the exocrine 
pancreas. Oncogenic driver mutations in KRAS are prevalent in approximately 90% of 
PDAC cases. Mutant KRAS drives tumor cell proliferation and viability through the 
activation of several downstream effector pathways, most prominently the MEK/ERK, 
PI3K/Akt, and mTOR pathways [248, 249]. We previously derived a gene expression 
signature of KRAS dependency in PDAC cell lines . The KRAS dependency signature is 
enriched with several kinase genes, including SYK and MST1R, which promote cell 
proliferation and survival. SYK encodes the spleen tyrosine kinase, which has pleiotropic 
functions, including regulation of innate and adaptive immune responses [149, 250]. SYK 
is expressed in epithelial cells but its epithelial-associated functions are poorly 
understood [146]. The overarching goal of this study was to investigate mechanisms of 
SYK kinase signaling in PDAC cell lines, including a potential role in modulating 
pathways downstream of KRAS, including MEK/ERK and PI3K/AKT/mTOR.  
 The mechanistic target of rapamycin (mTOR) is an evolutionarily conserved 
protein kinase that controls cellular metabolism. Two distinct mTOR complexes have 




signaling but the downstream biochemical functions of each complex are distinct, with 
mTORC1 primarily regulating protein translation via phosphorylation of p70 S6 kinase 
(p70S6K) and macroautophagy (referred to hereafter as autophagy) by phosphorylation 
an inhibition of the MiT/TFE family of transcription factors [251]. Autophagy is an 
evolutionarily conserved catabolic process that recycles cellular macromolecules under 
conditions of nutrient deprivation or metabolic stress [119-122]. Autophagy can be anti- 
or pro-tumorigenic depending on context [252]. During tumor initiation, autophagy 
promotes the degradation of damaged cellular organelles, including mitochondria. This 
prevents the accumulation of DNA-damaging reactive oxygen species (ROS). In this 
context, autophagy may function as a tumor suppressive mechanism. As tumors progress 
to malignancy, metabolic demands increase and autophagy becomes a mechanism to 
recycle intracellular macromolecules for growth and proliferation of cancer cells. The pro 
and anti-tumorigenic functions of autophagy are delicately balanced in tumor cells that 
are actively proliferating under nutrient-deprived conditions. 
 The autophagy pathway is constitutively-activated in advanced PDAC [138]. 
Concomitant activation of the mTOR pathway serves to limit autophagy pathway 
activation, highlighting a finely-tuned homeostatic control mechanism. Autophagy 
pathway activation is controlled by mTOR-dependent phosphorylation of the MiT/TFE 
family of transcription factors, which are comprised of MITF, TFEB and TFE-3 [253]. 
These factors regulate gene expression programs that promote lysosome/autolysosome 
biogenesis and subsequent activation of autophagy [254]. The MiT/TFE family of 




as a consequence of binding to 14-3-3 proteins [121, 138, 253]. In PDAC, MiT/TFE 
regulation is often decoupled from negative regulatory mechanisms, thus increasing 
MiT/TFE nuclear localization and transcriptional activity, leading to autophagy pathway 
activation [138]. The mTORC1 pathway limits MiT/TFE nuclear localization and 
transcriptional activity. Upstream mechanisms that control mTORC1-dependent 
regulation of MiT/TFE proteins and the autophagy pathway have not been fully resolved. 
In this study, we investigated the role of SYK in promoting PDAC cell proliferation, 
mTORC1 signaling, and regulation of MiT/TFE-dependent autolysosome biogenesis. 
Materials and methods 
Cell lines and reagents 
 PRT062607, everolimus, trametinib and hydroxychloroquine were purchased 
from SelleckChem Inc. PDAC cell lines were purchased from the American Type Culture 
Collection (ATCC) and Deutsche Sammlung von Mikroorganismen und Zellkulturen 
(DSMZ) cell line repositories. PDAC cell lines were maintained in RPMI 1640 (Gibco) 
supplemented with 5% fetal bovine serum (FBS), 1mM sodium pyruvate, 100 units/mL 
penicillin, and 100 µg/mL streptomycin using an incubator maintained at 37°C and 5% 
CO2. 293T cells were grown in DMEM (Gibco) with 10% FBS. 
Western blotting and antibodies 
 Cells were lysed in 1X Laemmli buffer with Pierce Phosphatase Inhibitor and 
Halt Protease Inhibitor (ThermoFisher Scientific). Cell lysates were then sonicated and 




lysates were loaded and separated by SDS-PAGE (12%) and transferred onto 
polyvinylidene fluoride (PVDF) membranes. A Syngene G-Box XT4 system or Bio-Rad 
ChemiDoc XRS+ imagers were used for ECL-based imaging (Pierce-Thermo, West-
Pico). The following antibodies were used for Western blotting: pAKT(S473), AKT, 
pERK(T202/Y204), ERK, LAMIN, LC3, pMEK(S217/221), MEK, MITF, p-RSK(S380), 
RSK, p-S6(S235/236), S6, p-p70S6K(T389), p70S6K, SYK, TFE3, TFEB, p-Tyr, (Cell 
Signaling Technology), p-ERK(Y204), GAPDH, and p62 (Santa Cruz Biotechnology). 
All antibodies were diluted in 2% BSA/TBS-T solution. Secondary anti-mouse or rabbit 
HRP-conjugated antibodies were used (Cell Signaling Technology). Densitometry 
measurements of Western blot bands were performed in the NIH Image-J software suite. 
Dose response assays 
 Cells were seeded in a 96-well plate at a density of 5000 cells/well 24 hours 
before the addition of PRT062607/SYKi or DMSO vehicle control. The cells were 
maintained for 72 hours post treatment at 37°C, 5% CO2. Subsequently, cells were fixed 
in 4% formaldehyde in 1X PBS and stained with 2µg/mL Hoechst 33342 (ThermoFisher 
Scientific) in 1X PBS for 20 minutes. Hoechst-stained nuclei were imaged with a 
Cytation 3 Cell Imaging system (BioTek). The integrated Gen5 Microplate Reader and 
Imager Software was used to count total nuclei number per well. 
Cell cycle high content imaging analyses 
 Hoechst-based nuclear fluorescence intensity was quantitated on a per object basis 




objects were plotted as a histogram. Histogram peaks corresponding to G1/S/G2/M phase 
boundaries were identified and intensity gates were set in Gen5 software to quantitate the 
relative proportion of cells with <2N (sub-G1), 2N (G1/S), 4N (G2/M), >4N DNA 
content. Compiled cell cycle data were plotted as a stacked bar plot. 
Lentiviral transduction 
 All shRNA constructs were purchased in the pLKO.1 backbone from the Broad 
Institute's RNAi Consortium (TRC). SYK-A and SYK-B constructs were obtained from 
Open Biosystems and cloned in the pLenti6 vector backbone by Gateway Cloning 
(Invitrogen Inc). Lentiviral particles were generated using a three-plasmid system in 
293T packaging cells, as described previously [255, 256]. Cells were transduced by spin-
infection with recombinant lentiviruses with 8 µg/mL polybrene at 1,200 x g for 1 hour. 
For stable selection of shRNA expressing cells, 1 µg/mL puromycin was used for 1 week. 
For stable selection of exogenous SYK expression, cells were treated with 10µg/ml 
blasticidin for 1 week. 
Immunoprecipitation 
 DAN-G cells were seeded in a 150mm culture dish at a density of 3.75 x 106 
cells/dish 24 hours before the addition of drug. The cells were either treated with SYKi or 
DMSO and incubated for 4 hours and lysed in HEPES lysis buffer (50mM HEPES, pH 
7.5, 150mM NaCl, 1% Triton X-100, 2.5% sodium deoxycholate and 10% glycerol). Cell 
lysates were normalized using Pierce BCA Protein Assay. A 50µL aliquot of lysate was 




p-Tyr antibody (Cell Signaling Technology) and Invitrogen Magnetic Protein-G 
Dynabeads. Beads were collected, washed with 3X with HEPES lysis buffer, and 
resuspended in 15µL 1X Laemmli buffer for analysis by SDS-PAGE and Western 
blotting. 
Clonogenic assays 
 Cells were seeded in a 12-well plate at a density of 1000 cells/well. The following 
day, cells were treated with SYKi and/or MEKi and maintained for 14 days at 37°C, 5% 
CO2. The cells were fixed with 4% formaldehyde in 1x PBS and stained with Giemsa 
dye (Ricca Chemical Company) diluted 1:50 in 1X PBS. A Bio-Rad ChemiDoc XRS+ 
was used to acquire plate images. Colonies were quantitated in NIH ImageJ using the 
Analyze Particles function to measure average colony size. 
LysoTracker assay 
 Cells were seeded in 96-well plates at 1.5x104 cells/well and drug treated the 
following day. 24 hours post-treatment, cells were incubated with 50nM LysoTracker 
Red DND-99 dye and 2.5µg/mL Hoechst 33342 (Molecular Probes/Life Technologies) in 
fresh RPMI growth media (Gibco). Media was replaced with fresh RPMI growth media 
and Lysotracker images were acquired using a λEx/λEm 577/590 nm filter set in a 
Cytation 3 imaging system (BioTek Inc.) equipped with a 10x objective lens. Automated 
Lysotracker puncta identification and counting were performed using Gen5 imaging 




Combination MEK and SYK inhibitor dose response assays 
 DAN-G cells were seeded at a cell density of 300 cells/well in 1536-well plates. 
DMSO treatment (0.3% DMSO final concentration) was compared to cells treated with 
the MEK inhibitor Trametinib either alone or in combination with PRT062607, using a 
HP D300 digital dispenser (Hewlett-Packard). The cells were then stained by adding 3 μL 
Hoechst 33342 (2 μg/mL final concentration) and LysoTracker Red DND-99 (Thermo 
Fisher; 100 nM final concentration) in RPMI, treated for 1 hr at 37°C/5% CO2, and 95% 
humidity. Cells were fixed with 8 μL of 1% PFA in 1x PBS. Images were collected on a 
Yokogawa CV7000 automated microscope in confocal mode using 1 field/well and a 
10x/0.4 NA objective. Hoechst stained nuclei were visualized using λex = 405nm and 
λem = 445nm and lysotracker was visualized using λex= 561nm and λem = 600nm. 
Image analysis was performed using the Yokogawa CV7000 image analysis software 
(Wako) to enumerate the number and fluorescence intensity values of nuclei and 
lysotracker objects. 
mCherry-GFP-LC3 live cell imaging 
 DAN-G and YAPC cells stably expressing pBabe-puro mCherry-EGFP-LC3B 
[257] were seeded into a 12-well plate at a density of 1.5 x 105 cells/well 24 hours before 
drug treatment. Cells were treated with SYKi, hydroxychloroquine, everolimus, or 
DMSO and followed immediately by live cell imaging. Cells were maintained at 37°C, 
5% CO2 for 24h during live cell image acquisition using a Cytation 3 imaging system 
(BioTek Inc.). Using a 10x objective lens, nine images per well were taken every 20 




586/647 nm filter sets, respectively. Red and green puncta were quantitated by image 
cytometry using Gen5 imaging software by empirically setting fluorescence intensity 
thresholds to identify dual fluorescent green/red puncta (AP) and red-only puncta (AL). 
Nuclear/cytoplasmic fractionation 
 Cells were seeded into a 60mm dish at 7.5x105 cells/dish and were treated with 
SYKi 24h post-plating. Cells were trypsinized 24h post-treatment and lysed in CSK 
buffer (10mM HEPES pH7.5, 10mM KCl, 2mM MgCl2, 300mM sucrose, 0.1% Triton X-
100) supplemented with Pierce Phosphatase Inhibitor and Halt Protease Inhibitor 
(ThermoFisher Scientific). A 50µL aliquot of the lysate was saved as whole cell extract 
while the remainder was centrifugated at 1.4 x g for 5 minutes to pellet the nuclear 
fraction. The supernatant was set aside as the cytoplasmic fraction and the nuclear pellet 
was lysed in 1X Laemmli sample buffer. Nuclear fractions and whole cell extracts were 
boiled in 1X Laemmlli buffer followed by analysis by SDS-PAGE and Western blotting. 
Gene expression analysis of primary PDACs from the TCGA 
 Normalized FPKM data of the Cancer Genome Atlas (TCGA) pancreatic 
adenocarcinoma (PAAD) data was downloaded from the Firebrowse repository. Data was 
imported and analyzed using the Qlucore Omics Browser software suite. First, k-means 
clustering was performed (k=5). SYK expression was analyzed in the 5 resulting clusters. 
Differential gene expression was performed by two-group analysis (p<4e-17), comparing 
cluster 5 (SYK-low cluster) to clusters 1-4 (SYK-high), yielding a list of 812 




(PCA) plots, box-plots and Kaplan-Meier plots were generated using Qlucore. Gene Set 
Enrichment Analyses (GSEA) were performed using datasets from the Broad Institute’s 
mSigDB using the Qlucore software. 
Results 
SYK kinase inhibition reduces cell proliferation in a subset of PDAC cell lines 
 We previously demonstrated that SYK mRNA and protein expression levels are 
elevated in mutant KRAS-dependent PDAC cell lines [31]. Ablation of SYK expression 
suppresses cell proliferation and survival of KRAS-dependent PDAC cells. This 
prompted our interest in investigating the functional role of SYK in promoting the 
proliferation and survival of PDAC cell lines. SYK protein expression is highly variable 
in PDAC cell lines, which can generally be classified into “SYK-low” and “SYK-high” 
subtypes (Fig. 2.1A). We chose two “SYK-high” cell lines (DAN-G, YAPC) and two 
“SYK-low” cell lines (KP-1N, PANC-1) for functional studies, due to their robust growth 
characteristics in cell culture and amenability to lentiviral-mediated genetic perturbations. 
 To study the functional consequences of SYK kinase inhibition, we used a 
selective SYK inhibitor, PRT062607 (SYKi), which is in pre-clinical testing for the 
treatment of inflammatory disorders and hematological cancers [258]. Kinase profiling 
data from the Medical Research Council UK shows that PRT062607 is a highly selective 
SYK kinase inhibitor, in vitro (http://www.kinase-screen.mrc.ac.uk/kinase-inhibitors). 
SYKi treatment of DAN-G, YAPC, KP-1N, and PANC-1 cells caused a dose-dependent 
decrease in cell proliferation (Fig. 2.1B). SYK-high DAN-G and YAPC cells were more 




KP-1N and PANC-1. In contrast, SYKi had no effect on the proliferation of an 
untransformed epithelial control cell line, MDCK.  
 To determine the effects of SYKi on global protein tyrosine phosphorylation, we 
treated DAN-G and YAPC cells with SYKi and performed Western blotting using anti-
phospho-tyrosine antibody. We observed SYKi dose dependent decreases in tyrosine 
phosphorylation of several proteins in both DAN-G and YAPC cells (Fig. 2.1C).  
 We assessed the effects of SYKi on the cell cycle in DAN-G and YAPC cells. 
Analysis of nuclear DNA content by image cytometry showed that SYKi treatment 
caused a dose-dependent decrease in the proportion of cells in G1/S cell cycle phases and 
a concomitant dose-dependent increase in the proportion of mitotic (G2/M phase) or 
polyploid cells. In summary, SYKi treatment of PDAC cell lines causes reduced cell 
proliferation, which is associated with decreased tyrosine phosphorylation of several 





Figure 2.1. SYK kinase inhibition causes reduced cell proliferation in PDAC cell lines. 
A, Western blot analysis of baseline SYK expression in a panel of KRAS-mutant PDAC cell lines, classified into SYK-
low and SYK-high subtypes. GAPDH serves as a loading control. B, Relative cell number as a function of dose 
following 72h PRT062607 (SYKi) treatment of DAN-G, YAPC, KP1N, PANC1, and MDCK cells. Data are presented 
as mean values of four replicates ±SEM. C, Western blot of global protein tyrosine phosphorylation in DAN-G and 
YAPC cells following treatment with SYKi at 1µM and 5µM doses. Cells were treated for 4h at the indicated doses or 






SYK inhibition promotes loss of mTORC1 activity in PDAC cell lines 
 To determine the mechanisms responsible for the anti-proliferative effects of 
SYKi in KRAS-mutant PDAC cell lines, we analyzed signaling pathways downstream of 
oncogenic KRAS, including activation of the MEK-ERK and the PI3K-AKT-mTOR 
pathways [259, 260]. SYKi treatment of DAN-G, YAPC, KP-1N, and PANC-1 cells 
caused a dose-dependent decrease in the phosphorylation of the mTORC1 substrate 
p70S6K and its target ribosomal protein S6 (S6) (Fig. 2.2A). Phosphorylation and 
activation of ERK was unchanged in SYKi-treated cells. Interestingly, SYKi treatment of 
SYK-expressing breast cancer cell lines, HCC1954 and DU4475, also caused reduced S6 
phosphorylation, indicating cross tissue regulation of mTORC1 by SYK. 
 SYK is autophosphorylated on Y525/526 in the activation loop of the kinase 
domain and on tyrosine residues in the linker region of the protein [172]. We validated 
the effects of SYKi on SYK kinase activity by measuring SYK phosphorylation by 
immunoprecipitation with a phospho-tyrosine specific antibody followed by Western 
blotting for SYK. This was performed in control or SYKi-treated DAN-G cells. We 
observed a SYKi dose-dependent decrease in SYK tyrosine phosphorylation indicating 
that SYKi blocks SYK kinase activity in DAN-G cells. We also measured SYK 
autophosphorylation at Y525/526 by Western blotting and observed a dose dependent 
decrease in DAN-G cells. SYK Y525/526 phosphorylation was below the limit of 
detection for the assay in YAPC, KP-1N, and PANC-1 cells under the same conditions as 




 Alternative splicing of SYK mRNA yields two isoforms, full length (SYK-A) and 
a truncated form (SYK-B), which lacks a 23 amino acid region in the linker region 
between the tandem SH2 domains and the kinase domain. We stably overexpressed both 
isoforms of SYK in DAN-G, YAPC, KP-1N, and PANC-1 cells and found that either 
SYK-A or SYK-B could promote phosphorylation of S6K. SYK-A caused increased 
p70S6K phosphorylation in DAN-G and YAPC cells, whereas SYK-B had no effect. In 
KP-1N and PANC-1 cells, both SYK-A and SYK-B caused increased p70S6K 
phosphorylation to varying extents. 
 Next, we performed a 6h time course experiment in SYKi-treated DAN-G cells, 
to determine the time latency between SYKi treatment and decreased S6 phosphorylation 
levels. We noted that the loss of S6 phosphorylation occurred 1h after 1μM SYKi 
treatment in DAN-G cells and decreased progressively over the 6h time course. At the 
higher dose of 5μM SYKi, S6 phosphorylation was completely abolished at 1h and 
remained undetectable for 6h (Fig. 2.2B). ERK phosphorylation levels did not change at 
any time point between 1h to 6h with SYKi treatment at either 1 or 5µM concentration. 
Phosphorylation and activation of AKT, which can promote mTORC1 activation in some 
situations [259], did not decrease with SYKi treatment. To validate the effects of SYKi 
on mTORC1 activity, we performed lentiviral shRNA transduction to deplete SYK in 
DAN-G, YAPC, KP-1N, and PANC-1 cells using two individual shSYK constructs. 
Knockdown of SYK caused decreased p70S6K and S6 phosphorylation with both shSYK 




that inhibition of SYK function in KRAS-mutant PDAC cell lines causes reduced 
mTORC1 activation, which occurs via ERK- and AKT-independent mechanisms. 
 
Figure 2.2. SYK inhibition causes dose- and time-dependent suppression of mTORC1 activity. 
A, Western blot analysis of dose-dependent SYKi effects (0.125 to 2µM range) in DAN-G, YAPC, KP-1N and PANC-
1 cells on phosphorylation of ribosomal protein S6 kinase (pp70S6K (T389)), S6 protein (pS6 (S235/236)), ERK MAP 
kinase (pERK (T202/Y204)) and SYK (pSYK (Y525/526)). DAN-G and YAPC cells were treated with SYKi for 4h. 
Total p70S6K, S6, ERK and SYK serve as loading controls. Data are representative of three independent experiments. 
B, Western blots showing time-dependent effects of SYKi (1 to 6h time course) in DAN-G cells at 1µM and 5µM 
concentrations. Data are representative of three independent experiments. C, Western blot analysis of p70S6K and S6 
phosphorylation following SYK knockdown by lentiviral shRNA transduction using two individual shSYK sequences 





Combined SYK and MEK inhibition causes an additive decrease in PDAC cell 
proliferation 
 Oncogenic KRAS drives MEK/ERK pathway activation to promote PDAC cell 
proliferation. SYK-mediated activation of mTORC1 in KRAS-mutant PDAC cells occurs 
via a MEK/ERK-independent mechanism, suggesting SYK and KRAS-MEK-ERK 
pathways may function in parallel. Therefore, we hypothesized that combined SYK and 
MEK kinase inhibition would cause additive or synergistic anti-proliferative effects in 
KRAS mutant PDAC cell lines. To test this hypothesis, we combined SYKi with the 
MEK inhibitor Trametinib (MEKi), which is FDA approved in for the treatment of 
melanoma. MEKi treatment (1μM) for 4h caused moderate or no suppression of S6 
phosphorylation in YAPC, DAN-G, KP-1N and PANC-1 cells. We verified that MEKi 
caused robust loss of ERK and downstream p90-RSK phosphorylation at serine 380 (Fig. 
2.3A). SYKi treatment caused dose-dependent suppression of S6 phosphorylation, which 
was additively suppressed when combined with MEKi. Neither MEKi nor SYKi caused 
significantly changes in phosphorylation of MEK or AKT at serine 473 (S473), a site 
targeted by the mTORC2 kinase complex. 
 The effects of combined MEKi and SYKi on the proliferation of DAN-G cells 
were tested in a 3-day dose response assay. MEKi cause strong suppression of DAN-G 
cell proliferation, which was additively suppressed when combined with SYKi, as 
indicated by a leftward shift in the dose response curve. Based on these results, we 
determined the effects of MEKi/SYKi combination treatment on clonogenic growth of 




noted that treatment of cells with 0.5µM SYKi or 20nM MEKi caused decreased 
clonogenic growth over 14 days in both DAN-G and YAPC cells. SYKi (0.5µM) alone 
had no effect on KP-1N and PANC-1 clonogenic growth. SYKi and MEKi combination 
treatment caused additive decreases in clonogenic growth in DAN-G (p = 0.0178), YAPC 
(p = 0.0164) and KP-1N (p = 0.0345). Suppression of PANC-1 clonogenic growth 
following SYKi/MEKi combination treatment was not significantly additive. In 
summary, we conclude that MEK and SYK cooperate in parallel and convergent 
signaling pathways to drive PDAC cell proliferation. The anti-proliferative effects of 
combined MEK and SYK inhibition are more pronounced in the SYK-high DAN-G and 





Figure 2.3. SYKi and trametinib (MEKi) in combination causes additive suppression of mTORC1 signaling and 
decreased PDAC clonogenic growth. 
A, Western blot analysis of SYKi/MEKi-treated DAN-G, YAPC, KP1N, and PANC1 cells, showing levels of indicated 
phosphorylated (p) or total (t) proteins. Cells were treated for 4 hours at the indicated doses. Total S6, MEK, ERK, 
RSK, AKT and GAPDH levels serve as loading controls. Data are representative of three independent experiments. B, 
Images and quantitation of DAN-G, YAPC, KP1N, and PANC1 clonogenic growth after treatment with indicated doses 
of MEKi and SYKi for 14 days. Quantitation of colony size from images is based on pixel density. Data are shown as 






SYK inhibition promotes increased lysosome biogenesis in PDAC cell lines 
 Activation of mTORC1 causes suppression of lysosome biogenesis, via inhibition 
of the MiT/TFE family of transcription factors (MITF, TFEB and TFE-3) [120, 121]. 
Therefore, we hypothesized that SYK-mediated regulation of mTORC1 in PDAC cell 
lines could serve as a mechanism to maintain homeostatic control of 
lysosome/autolysosome biogenesis and autophagy pathway activation. To test this 
hypothesis, we tracked lysosome number using LysoTracker Red (DND-99) dye, which 
is a membrane permeable dye consisting of a fluorophore conjugated to a weak base that 
fluorescently labels acidic lysosomes. LysoTracker Red dye labels all acidic lysosomes 
but fluorescence is not proportional to pH.  
 We performed time course experiments to measure SYKi-mediated changes in 
lysosome number, as quantitated by the number of LysoTracker-positive fluorescent 
puncta. We treated DAN-G cells with increasing doses of SYKi and quantitated lysosome 
number by image cytometry over a 24h time course. We observed both a dose- and time-
dependent increase in the number of total lysosomes after SYKi treatment (Fig. 2.4A, 
2.4B). We hypothesized that this increase in lysosome number was due to suppression of 
mTORC1 activity. As a positive control, we confirmed that direct inhibition of mTORC1 
activity with everolimus caused increased lysosome accumulation, to a similar extent as 
SYKi treatment in PDAC cell lines (Fig. 2.4C). Everolimus treatment of PANC-1 cells, 
induced a weaker, albeit significant accumulation of lysosomes in PANC-1 cells 




 Next, we determined that combined MEKi and SYKi treatment caused additive 
increases in lysosome number. Treatment of DAN-G, and YAPC cells with 0.25µM 
MEKi caused a leftward shift in the SYKi dose response curve for lysosome number fold 
change. However, the additive effects of MEKi/SYKi were not significant in in KP-1N 
and PANC1 cells (Fig. 2.4D). 
 To validate the effects of SYKi, we quantitated lysosome number following 
shRNA-mediated SYK depletion. SYK knockdown by lentiviral shRNA delivery in 
PDAC cell lines caused an increase in the number of lysosomes, similar to the effects of 
SYKi treatment (Fig. 2.4E, 2.4F). The effect of SYK knockdown on increased lysosome 
accumulation was consistent in both DAN-G and YAPC cells. When comparing SYK-
low KP-1N and PANC-1 cell lines to SYK-high DAN-G and YAPC cells we noted that 
the SYK-low cell lines had higher baseline lysosome number (Fig. 2.4F). However, fold 
increase in lysosome number following SYK knockdown was significantly higher in 
DAN-G and YAPC SYK-high cells. Finally, we observed that overexpression of SYK in 
DAN-G and KP-1N cell lines caused a significant reduction in lysosome number. The 
effects of SYK overexpression on lysosome number in YAPC and PANC-1 cells were 
not significant. In summary, we conclude that SYK suppresses lysosome biogenesis, 





Figure 2.4. SYK inhibition promotes increased lysosome size and number in PDAC cell lines. 
A, Fluorescence micrographs of LysoTracker Red DND-99 stained DAN-G cells treated with the indicated doses of 
SYKi. Images were obtained 24h after SYKi treatment. Scale bar = 100µm. B, Quantitation of LysoTracker stained 
puncta (lysosomes) as depicted in panel A, as measured by image-based cytometry. Graph shows SYKi dose-dependent 
fold increases in high intensity lysosome count compared to vehicle control ±SEM at four different indicated time 
points. Data are representative of three independent experiments. C, Effects of everolimus and SYKi on lysosome 
count in DAN-G, YAPC, KP1N, and PANC1 cells. Cells were treated with 1µM Everolimus, 1.25µM SYKi, or DMSO 
vehicle control. Bar plots show fold increases in high intensity lysosome count compared to vehicle control ±SEM 24h 
after drug treatment. * p ≤ 0.05; ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001 D, Effects of combined SYKi and MEKi 
on lysosome count in DAN-G, YAPC, KP1N, and PANC1 cells. Increasing doses of SYKi were used in combination 
with DMSO control or with 0.25µM MEKi. Data are presented as the mean of three replicates ±SEM. E, Fluorescence 
micrographs of LysoTracker-stained DAN-G, YAPC, KP1N, PANC1 cells, lentivirally transduced with shLUC or two 
individual SYK-directed shRNAs (2/3). F, Quantitation of average lysotracker puncta per cell in DAN-G, YAPC, KP-
1N, and PANC-1 cells (upper panel). Lower panel shows fold increases in normalized lysosome count in shSYK2/3-
transduced DAN-G, YAPC, KP1N, and PANC1 cells compared to shLuc control cells. Data in panels E and F are 




SYK inhibition promotes activation of the autophagy pathway in PDAC cell lines 
 The mTORC1 kinase complex suppresses autophagy via two key mechanisms. 
First, mTORC1 phosphorylates and inhibits the ULK1 kinase, which controls initiation of 
autophagosome assembly [119]. Second, the formation of mature autolysosomes is 
negatively regulated by mTORC1 through transcriptional control of MiT/TFE proteins. 
The various stages of autophagy pathway activation can be measured by analyzing 
protein expression levels, post-translational modification and aggregation of the 
microtubule-associated protein 1 light chain 3 (LC3/Atg8) [261-263]. Initiation of the 
autophagy pathway involves LC3 cleavage to generate LC3-I which then becomes lipid 
conjugated with phosphatidylethanolamine (PE) to generate the active membrane-bound 
form, LC3-II. SYKi treatment of DAN-G and YAPC cells caused dose-dependent 
increases in LC3-II protein levels (Fig. 2.5A). SYKi treatment also caused a moderate 
increase in protein levels of the autophagy adaptor p62/SQSTM1 in DAN-G cells. In 
YAPC cells, p62 protein levels did not change significantly in response to SYKi 
treatment. 
 Increased abundance of LC3-II protein could indicate a block in the formation of 
mature autolysosomes, which normally degrade LC3-II. To confirm that SYKi treatment 
promotes rather than blocks the formation of autolysosomes, we performed an assay that 
is commonly used to track the relative accumulation of autophagosomes (APs) and 
autolysosomes (ALs) in real time. To that end, we employed the dual-fluorescent 
mCherry-EGFP-LC3B reporter [257, 264, 265]. Processed LC3B-II is incorporated into 




overlap). APs mature into autolysosomes (ALs) following fusion with acidic lysosomes. 
The acidic environment in ALs causes quenching of GFP fluorescence on the LC3B-II 
reporter protein leaving only mCherry red fluorescent signal. Thus, ALs can be visualized 
in the cell as red fluorescent LC3B-II aggregates/puncta. 
 We stably introduced mCherry-GFP-LC3 in DAN-G and YAPC cells by 
retroviral transduction to generate reporter cell lines. These reporter cells were treated 
with 1µM or 5µM SYKi. As positive controls for blockade or activation of autophagy, 
we used the lysosomotropic agent hydroxychloroquine (HCQ) at 50µM and everolimus at 
2µM, respectively. HCQ prevents lysosome/autophagosome fusion, resulting in the 
accumulation of autophagosomes that fail to mature into functional autolysosomes. Live-
cell fluorescence imaging of mCherry and GFP was performed over a 24h time course in 
DAN-G cells (Fig. 2.5B) and YAPC cells. We quantitated the percent of AL puncta as a 
proportion of total AP+AL puncta (% AL). In vehicle-treated DAN-G cells, % AL 
decreased moderately over a 24h time course (Fig. 2.5B, 2.5C). Chloroquine treatment 
caused a progressive decrease in % AL, indicative of a block in AL maturation, as 
expected. In contrast, % AL increased over time in SYKi-treated cells, used at doses of 
1μM and 5μM (Fig. 2.5C). The effect of SYKi on AL accumulation was similar to the 
effect of the positive control, everolimus. The effects of SYKi on AL accumulation were 
tested in YAPC cells, with similar results obtained to those of DAN-G. 
 Lastly, we analyzed basal expression of autophagy pathway-related proteins in a 
panel of PDAC cell lines. AMPK-dependent phosphorylation of Beclin 1, was reduced in 




PANC-1). ATG7 protein expression was comparatively low in YAPC and DAN-G cells. 
In contrast, basal levels of phospho-S6 were high in YAPC and DAN-G compared to the 
SYK-low cell lines. In summary, SYK suppresses autolysosome biogenesis in PDAC cell 
lines and high SYK expression is correlated with reduced basal expression of some 





Figure 2.5. SYK inhibition promotes autophagy pathway activation. 
A, Western blot analysis of LC3 and p62 expression in SYKi-treated DAN-G cells (24h treatment). Data are 
representative of three independent experiments. B, Live cell imaging of DAN-G cells expressing mCherry-GFP-LC3B 
and treated with SYKi, everolimus, or chloroquine at indicated doses over a 24h time course. C, Image cytometry-
based quantitation of autolysosomes (red puncta) as a percentage of total puncta (yellow and red) under indicated 
inhibitor treatment conditions. Data are presented as the total puncta from 25 separate images and are representative of 





SYK regulates MITF-dependent lysosome biogenesis and autophagy 
 To further explore the mechanism by which SYK controls autolysosome 
accumulation, we investigated the MiT/TFE family transcription factors. To that end, we 
performed subcellular fractionation of SYKi- and everoliumus-treated YAPC and DAN-
G cell lysates. Subsequently, we analyzed protein levels of TFEB, MITF and TFE-3 in 
nuclear and cytoplasmic fractions (Fig. 2.6A). Western blot analysis revealed a SYKi 
dose-dependent increase in nuclear MITF as a proportion of MITF in the whole cell 
extract (WC). In addition, nuclear TFEB increased moderately with SYKi treatment. The 
positive control, everolimus had similar effects on nuclear accumulation of TFEB and 
MITF. TFE-3 was expressed at low levels in YAPC cells, mostly present in the 
cytoplasmic fraction with no detectable change in nuclear accumulation in response to 
SYKi or everolimus. Densitometric quantification of Western blot data for the nuclear 
and total fractions of MITF showed that the ratio of nuclear to total (WC) MITF 
increased two-fold in response to 1µM SYKi treatment (Fig. 2.6B). 
 To validate MITF as a key mediator of lysosome accumulation in SYKi-treated 
cells, we performed shRNA-mediated MITF depletion with two different shRNAs 
targeting MITF (A and C) in KP-1N, PANC-1, DAN-G, and YAPC cells. MITF 
depletion caused a pronounced suppression of total lysosome number in DAN-G and 
YAPC cells as assessed by LysoTracker fluorescent signal, in both DMSO control and 
SYKi-treated YAPC cells (Fig. 2.6C, 2.6D). Quantitation of normalized lysosome count 
(as a proportion of total cell count) showed that MITF depleted DAN-G and YAPC cells 




2.6D). SYKi treatment of MITF depleted YAPC and DAN-G cells resulted in attenuated 
accumulation of lysosomes. In contrast, MITF depletion had minimal effects on lysosome 
number in the SYK-low KP-1N and PANC-1 cell lines. In MITF-depleted KP-1N cells, 
SYKi treatment had a diminished effect on lysosome accumulation compared to control 
cells. However, the effects of MITF depletion on lysosome number in PANC-1 cells were 
not significant. Validation of MITF protein knockdown in shMITF-A/C expressing KP-
1N, PANC-1, DAN-G, and YAPC cells was performed by Western blotting (Fig. 2.6E). 
In summary, we conclude that the effects of SYKi on lysosome biogenesis are mediated, 





Figure 2.6. SYK inhibition promotes MITF-dependent lysosome biogenesis. 
A, Western blot analysis of nuclear and cytoplasmic expression of MiT/TFE family transcription factors in YAPC cells 
treated with 0.5µM/1µM SYKi or 2µM everolimus for 24h. LAMIN A/C protein expression is shown to verify nuclear-
specific fractionation and GAPDH expression verifies cytoplasmic-specific fractionation. Data are representative of 
three independent experiments. B, Densitometric quantitation of nuclear:total ratios of MITF protein in YAPC cells 
relative to DMSO control from Western blot data depicted in panel A. C, Representative fluorescence micrograph 
images of LysoTracker Red staining in PANC1 and YAPC cells transduced with shLUC (control) or shMITF-A/C and 
treated with 1uM SYKi for 24h. D, Image cytometry-based quantitation of lysosome count in KP-1N, PANC-1, DAN-
G, and YAPC cells from the experiment depicted in panel C. Data are represented as the mean of three replicates 
±SEM. E, Western blots showing MITF protein expression in KP-1N, PANC1, DAN-G, and YAPC cells used for 





Autophagy is transcriptionally activated in a “SYK-low” molecular subtype of PDAC 
 To determine if SYK expression is associated with autophagy pathway 
perturbations in vivo, we analyzed RNA-seq based transcriptomic data from the Cancer 
Genome Atlas (TCGA) for the pancreatic cancer adenocarcinoma (PAAD) patient cohort 
[266]. First, we used k-means clustering to identify 5 distinct molecular subtypes. 
Clusters 1, 2, 3 and 4 are closely related by variances of gene expression as assessed by 
3-dimensional principal components analysis (PCA) (Fig. 2.7A). In contrast, a divergent 
cluster 5 was identified. Upon closer inspection of gene ontologies associated with cluster 
5, we noted that this resembles the “squamous” or “quasi-mesenchymal” molecular 
subtype identified by Collisson et al. and Bailey et al. [18, 32]. This subtype is 
characterized by weak expression of epithelial differentiation markers. We noted that 
cluster 5 had low expression of SYK, consistent with low SYK expression in 
mesenchymal-like PDAC cell lines (e.g. KP-1N and PANC-1). Concomitant with low 
SYK expression in cluster 5, we noted low expression of RPTOR (encoding Raptor) and 
high expression of ULK1 and ULK2 (autophagy-activating kinases) (Fig. 2.7B). 
Furthermore, MAP1LC3A (encoding the LC3A autophagosome protein) as well as 
vacuolar ATPase encoding ATP6V0A1, ATP6V1G1 genes show elevated expression in 
cluster 5 (Supplementary Fig. S6A). Next, we performed Gene Set Enrichment Analysis 
(GSEA) on differentially expressed genes in cluster 5. We observed significant 
enrichment for genes associated with mTOR pathway inhibition. Finally, we noted that 
cluster 5 is associated with better overall survival compared to clusters 1-4, as assessed 




PDACs reveals a molecular subtype which is associated with squamous molecular 
characteristics, low SYK expression, low mTOR and high autophagy pathway activation 
and better patient prognosis. 
 
Figure 2.7. SYK expression is correlated with decreased mTORC1 and autophagy related gene expression in 
human PDAC. 
A, Principal Component Analysis (PCA) of k-means clusters (1-5) of PDACs from the TCGA dataset. B, Box-plots 
showing gene expression scores for indicated genes in the 5 clusters depicted in panel A. Cluster 5 represents a “SYK-
low” molecular subtype. Genes were selected for relevance to the mTOR and autophagy pathways. RPTOR encodes 







 The SYK tyrosine kinase is abundantly expressed in many PDAC cell lines. To 
date, SYK kinase-dependent functions in PDAC have not been comprehensively 
investigated. In this study, we used a selective SYK kinase inhibitor (PRT062607/SYKi) 
to determine that SYK regulates PDAC cell proliferation partly through activation of the 
mTORC1 signaling pathway. SYK regulation of mTORC1 positively controls 
phosphorylation and activation of ribosomal protein S6 by its upstream kinase p70S6K, 
which is associated with increased CAP-dependent protein translation [267]. S6 
phosphorylation can also be mediated by the ERK-regulated p90-RSK kinase. Our data 
indicate that SYKi treatment of DAN-G PDAC cells does not affect ERK-RSK signaling, 
indicating that the effects of SYKi on S6 phosphorylation are predominantly mediated by 
the mTORC1-p70S6K signaling pathway (see Fig. 2.2A). Importantly, SYK controls 
mTORC1-dependent effects on the autophagy pathway. Decreased mTORC1 activity in 
SYKi-treated PDAC cells occurs independently of MEK/ERK and PI3K/AKT signaling 
pathway activation. This suggests that SYK controls mTORC1 via an unknown 
mechanism. The molecular mechanisms by which SYK controls mTORC1 will be an 
interesting avenue for future studies.  
 Our findings are consistent with studies that demonstrate SYK promotes 
mTORC1 activation in follicular lymphoma and acute lymphoblastic leukemia (ALL) 
[184-186]. Moreover, genetic or pharmacological SYK perturbation causes reduced 
mTORC1 activation in the context of brown fat differentiation [183]. A recent study 




mTORC1 [268]. Our studies are the first to investigate SYK regulation of mTOR 
signaling in PDAC. As SYK regulation of mTORC1 functions in parallel with 
MEK/ERK signaling, we hypothesized that combined SYK and MEK inhibition would 
promote additive anti-proliferative effects on PDAC cell lines, which we successfully 
demonstrated in this study. In future studies, combination approaches with SYKi and 
compounds that target additional nodes in KRAS and mTOR signaling networks will be 
tested for synergy in promoting PDAC cell killing. 
 The mTORC1 complex blocks activation of the autophagy pathway under normal 
growth conditions, when the supply of amino acids and other nutrients is high. However, 
autophagy is constitutively activated in PDAC tumors and cell lines [252, 269, 270]. The 
role of autophagy in cancer progression is controversial, because the pathway can cause 
tumor suppression in some contexts. For example, the essential autophagy regulator 
Beclin 1 is a haploinsufficient tumor suppressor in mice [271]. Homeostatic maintenance 
of autophagy is important for sustaining the nutrient demands of highly proliferative 
cancer cells, for example KRAS-mutant PDAC cells. Our studies show that the 
autolysosome biogenesis is increased after SYKi treatment. Autophagy is constitutively 
activated in PDAC cell lines used in this study, as determined by basal levels of LC3-II 
protein aggregates in autolysosomes (see Fig. 2.5B). We demonstrated that SYK 
inhibition or shRNA-mediated depletion in YAPC and DAN-G cells caused increased 
production of the mature processed LC3-II protein [261, 263, 264] and associated 
increases in autolysosome biogenesis, as demonstrated by live cell imaging of the 




results in activation of autolysosome biogenesis. We hypothesize that SYK controls 
mTORC1 activation to maintain homeostatic control of autophagy, which can be 
cytotoxic if hyperactivated. As a consequence of SYK inhibition, perturbations in the 
autophagy pathway cause suppression of PDAC cell proliferation. 
 MIT/TFE-family transcription factors (MITF, TFEB, and TFE-3) are master 
regulators of autophagy pathway activation and autolysosome biogenesis [120, 138, 253, 
254]. Cytoplasmic retention and inhibition of MiT/TFE factors is regulated by the 
mTORC1 kinase complex. In pancreatic cancer, MiT/TFE activity can promote tumor 
progression [138]. Our results show that mTORC1 inactivation as a consequence of SYK 
inhibition causes increased nuclear localization of MITF and subsequent promotion of 
autolysosome biogenesis. Moreover, MITF depletion in YAPC and DAN-G cells blocks 
lysosome biogenesis and severely abrogates the effects of SYK inhibition on increased 
lysosome biogenesis. The effects of MITF depletion on lysosome biogenesis in KP-1N 
and PANC-1 cells is less pronounced, suggesting an alternative mechanism that controls 
formation of lysosomes in the SYK-low cell lines. Another mechanism that regulates 
autophagosome formation downstream of mTORC1 is mediated by the ULK1 kinase. 
However, ULK1 controls early stages of autophagy pathway initiation rather than later 
stages of autolysosome formation. Furthermore, ULK1 does not control LC3 protein 
cleavage and lipidation [119, 262, 272]. SYK inhibition does not significantly affect 
autophagosome formation. Therefore, we conclude that SYKi-mediated effects on 




 We initially hypothesized that SYK-high cell lines would be more sensitive to the 
anti-proliferative effects of SYK inhibition than SYK-low cell lines would not. 
Surprisingly, SYK inhibition affected cell growth, mTORC signaling, and lysosome 
biogenesis in SYK-high and SYK-low cell lines. This indicates that SYK is functionally 
active in the SYK-low cell lines, with regard to control of mTORC1 signaling and 
autophagy pathway activation. Of note, SYKi treatment does have a more pronounced 
effect on clonogenic growth of SYK-high cell lines in comparison to SYK-low cell lines. 
Importantly, SYK expression levels are inversely correlated with baseline lysosome 
number (see Fig. 2.4F). Moreover, SYK overexpression in SYK-low cell lines causes 
mTORC1 activation to suppress lysosome accumulation. 
 Previous studies have implied that SYK promotes tumor suppression in PDAC 
and breast cancer. In contrast, our findings implicate SYK as an oncogenic driver via 
activation of mTOR signaling. Our analysis of the TCGA PAAD dataset correlates low 
SYK expression with better overall survival, in contrast to studies of SYK in breast 
cancer. In hematopoietic cancers, SYK is considered to be pro-tumorigenic [273] 
consistent with our functional studies of SYK in PDAC. 
 Recent studies indicate that MEK and ERK inhibition cause activation of the 
autophagy pathway, which may function as a “resistance” mechanism to MEK/ERK 
inhibition in PDAC [142-144]. Hence, combining MEK/ERK inhibition with autophagy 
blockade resulted in an enhanced antiproliferative effect in PDAC cell lines and caused 
tumor regression in one PDAC patient who received the combined therapy. These studies 




Future studies will be aimed at investigating the efficacy of SYK kinase inhibition in 
combination with other agents to perturb homeostatic control of autophagy for 
therapeutic benefit. 
 In summary, our studies demonstrate that SYK activates the mTORC1 kinase 
complex in PDAC cell lines, which allows for homeostatic control of the autophagy 
pathway. SYK kinase inhibition blocks mTORC1 activation, resulting in enhanced MITF 
nuclear accumulation and activation of the autophagy pathway. Decreased mTORC1 
activity and perturbation in autophagy pathway dynamics causes reduced cell 
proliferation in PDAC cell lines. Our studies will open new avenues to explore synthetic 
lethal approaches that combine SYK inhibition with other KRAS-dependency associated 




CHAPTER THREE: REGULATION OF AUTOPHAGY, NF-ΚB SIGNALING, 
AND CELL VIABILITY BY MIR-124 IN KRAS MUTANT MESENCHYMAL-
LIKE NSCLC CELLS 
Abstract 
 KRAS mutant non–small cell lung cancer (NSCLC) may be classified into 
epithelial or mesenchymal subtypes. Despite having the same “driver” mutation, 
mesenchymal NSCLCs are less responsive than are epithelial NSCLCs to inhibition of 
the RAS pathway. Identifying alternative networks that promote survival specifically in 
mesenchymal NSCLC may lead to more effective treatments for this subtype. Through 
their numerous targets in cellular signaling pathways, noncoding microRNAs (miRNAs) 
often function as tumor suppressors or oncogenes. In particular, some miRNAs regulate 
the epithelial-mesenchymal transition (EMT). We derived an EMT-related miRNA 
signature by profiling the abundance of miRNAs in a panel of epithelial (KE) or 
mesenchymal (KM) KRAS mutant NSCLC cell lines. This signature revealed a number 
of suppressed miRNAs in KM cell lines, including members of the miR-200 family, 
which can suppress tumor progression by inhibiting EMT. Reconstituting KM cells with 
one of these miRNAs, miR-124, disrupted autophagy and decreased cell survival by 
reducing the abundance of p62, which is both an adaptor for selective autophagy and a 
regulator of the transcription factor nuclear factor κB (NF-κB). Suppression of p62 by 
miR-124 correlated with reduced abundance of the autophagy activator beclin 1 
(BECN1), the ubiquitin ligase TRAF6, and the NF-κB subunit RELA/p65. The 




patient NSCLC samples. These findings reveal how the loss of miR-124 promotes cell 
survival networks in the aggressive mesenchymal subtype of KRAS mutant NSCLC, 
which might lead to improved subtype-selective therapeutic strategies for patients. 
Introduction 
 Non–small cell lung cancers (NSCLCs) are aggressive and difficult to treat if 
diagnosed at advanced stages. A critical barrier to identifying effective therapeutics for 
NSCLCs, as well as many other related tumor types, is tumor cell plasticity that can lead 
to inter- and intratumoral molecular heterogeneity [274]. Global gene expression 
profiling of NSCLCs has revealed a number of heterogeneous and contrasting molecular 
subtypes that associate with distinct histopathological characteristics and therapeutic 
vulnerabilities [275, 276]. Oncogenic KRAS mutations are found in 20 to 30% of 
NSCLC cases but do not stratify into a uniform molecular or histological subtype. KRAS 
mutant NSCLC cell lines display highly variable KRAS-dependent transcriptional 
networks and cell survival pathways [31]. KRAS mutant NSCLC cells with epithelial 
morphology tend to be more dependent on KRAS for survival in contrast to KRAS 
mutant mesenchymal cells, which tend to have diminished KRAS dependency. These 
contrasting subtypes are subsequently designated KE (epithelial) and KM 
(mesenchymal). The underlying molecular mechanisms that contribute to reduced KRAS 
dependency in the KM subtype remain unclear. It is possible that co-occurring mutations 
in STK11/LKB1 and KEAP1 along with KRAS may confer reduced oncogenic KRAS 
dependency and provoke altered sensitivity to therapeutic agents [277, 278]. Many KM 




transition (EMT) is also associated with reduced sensitivity to some targeted therapeutic 
agents in vitro and drug resistance in vivo [274, 279]. 
 We previously compared microarray-based gene expression data for KE and KM 
cell lines and derived a KE/KM gene expression signature that associates strongly with 
oncogenic KRAS dependency and is enriched with EMT markers such as CDH1/E-
cadherin [31]. Preliminary association studies of this signature using the Oncomine 
Concepts Map [280] revealed a significant overlap with predicted miRNA target genes 
for miR-205 and miR-34. This provided a rationale to determine the functional 
significance of altered miRNA expression patterns in the context of 
epithelial/mesenchymal subtype of KRAS mutant NSCLC cell lines. The role of 
noncoding microRNAs (miRNAs) in the pathogenesis of lung cancer is highlighted by 
gene ablation studies of the processing enzyme DICER1 in a genetically engineered 
mouse model of mutant KRAS-driven lung cancer, which causes increased 
aggressiveness and size of tumors [281]. In some cases, the function of miRNAs can be 
oncogenic, as highlighted by the role of miR-21 in KRAS-driven lung cancer progression 
[282]. 
 In human cancers, miRNAs are globally down-regulated, suggesting general 
tumor suppressor functionality [283]. A number of individual miRNAs have tumor 
suppressor properties, including the let-7 family, which suppress MYC and KRAS 
oncogene expression [284, 285]. Also, the p53-regulated miR-34 family modulates some 
tumor suppressor functions including DNA damage response pathways [286]. Last, the 




[287]. Our goal was to identify miRNA gene regulatory networks that modulate epithelial 
differentiation and cell viability in KM subtype cells. Here, we derived a putative KE-
KM subtype miRNA signature. Subsequently, we characterized the functional role of 
KE-correlated miRNAs in modulating EMT, autophagy, and cell death in KM subtype 
cells, with an overarching goal of identifying context-dependent, subtype-selective cell 
survival pathways that could be exploited for therapeutic benefit in the future. 
Methods 
Quantitative profiling of miRNA expression in cell lines 
 Cells were grown to confluency in 60-mm dishes, trypsinized, and pelleted. Total 
RNA was extracted from cells using the Qiagen miRNeasy kit. miRNA expression was 
quantitated by qRT-PCR using TLDAs, as described previously [288]. Raw TLDA data 
and are publicly available via the NIH GEO online portal (accession number 
GSE102298). Expression data were processed in MS Excel to generate a volcano plot and 
to identify differentially expressed miRNAs in KE versus KM cells. Data were further 
processed in “R” equipped with the “pheatmap” package to perform hierarchical 
clustering and to generate a heat map of differentially expressed miRNAs. 
qPCR assays for miRNA and mRNA abundance 
 Abundance of mature miRNAs in cell lines was measured using the miScript 
qRT-PCR system (Qiagen Inc.). Briefly, cells were lysed in QIAzol reagent after 
transfection with siKRAS (48 hours after transfection) or under control conditions. Total 




using the miScript HiFlex buffer, to generate cDNA for small noncoding RNA and 
mRNA. PCR assays were performed on 1:50 diluted cDNA using sequence-specific 
primers and the Quantitect SYBR Green PCR mix. PCR products were detected using an 
Applied Biosystems Step One Plus instrument. Threshold cycle (Ct), ∂Ct, and ∂∂Ct 
were generated with the Step One Plus software. Data were normalized to abundance of 
endogenous SNORD6 RNA for miRNA quantitation or to GAPDH abundance for 
mRNA quantitation. 
Cell lines, miRNA mimics, and siRNA transfections 
 Human cancer cell lines (H460, A549, SKLU1, H2030, SW900, H1792, LU65, 
SW1573, H2009, H322, H358, H358M, H441, and MCF7) were grown in RPMI 
supplemented with 5% fetal bovine serum (FBS) (heat-inactivated at 50°C), 1 mM 
sodium pyruvate, and penicillin/streptomycin, as described previously [31, 289]. For 
initial small-scale screening, miRNA mimic and NC dsRNA oligonucleotides were 
purchased from Dharmacon Inc. in a 96-well arrayed format. Cells were transfected with 
RNAiMax reagent (Invitrogen) at 10 nM. For subsequent follow-up studies, NC and 
miRNA mimics were purchased from Qiagen and transfected at 10 or 50 nM for 
signaling pathway analyses by Western blotting. siRNA (dsRNA) oligonucleotides 
against SQSTM1 and KRAS were obtained from Integrated DNA Technologies and used 




Cloning of the pri-MIR124 lentiviral vector 
 Genomic DNA from 293T cells was used as a template to PCR-amplify the 
human primary MIR124-2 gene sequence (chr 8p12.3) using flanking forward/attB1 and 
reverse/attB2 Gateway cloning adapter primers. A two-step Gateway PCR protocol was 
used to clone the MIR124-2 605 nucleotide sequence into pDONR-223 and then into a 
Gateway-compatible pWPI lentiviral vector backbone (gift from D. Trono, Addgene 
plasmid #12254) using BP and LR clonases, respectively. Cloned sequences were 
verified by automated DNA sequencing. All viral vectors were packaged and generated 
in 293T cells using previously described methods [31, 290]. 
UTR reporter plasmid cloning and luciferase assay 
 A 1.2-kb DNA fragment corresponding to the 3′UTR of SQSTM1, with putative 
miR-124 binding sites, was PCR-amplified from human 293T cell genomic DNA by PCR 
using forward and reverse Gateway adapter primers. Mutant 3′UTR sequences lacking 
the critical base-pair complementarity within the 8-mer miR-124 seed sequence were 
generated by site-directed mutagenesis using the QuikChange kit (Agilent Inc.). 
SQSTM1 3′UTR DNA fragments were cloned into a modified pWPI lentiviral vector 
containing an upstream firefly luciferase gene driven by an EF-1α promoter. All clones 
were sequence-verified by DNA sequencing. For luciferase assays, cells were transduced 
with wild-type or mutant pWPI-SQSTM1 3′UTR lentiviral vectors. A similar approach 
was used for cloning of the BECN1 3′UTR. LUC-3′UTR–transduced cells were 




transfected with miR-124 mimics or NCs at 50 nmol/μl with Lipofectamine RNAiMAX 
(Invitrogen) according to the manufacturer’s recommendations. Two days after 
transfection, cells were treated with D-luciferin (100 μg/ml) and incubated at 37°C for 5 
min, and “glow-based” luminescence was measured with Fluostar Optima plate reader 
(BMG Labtech) with a 5-s integration time. Relative luciferase activity was normalized 
to the vector control (pWPI-luciferase vector) and NC miRNA mimic control. 
Cell viability and apoptosis assays 
 Cells were plated in 96-well plates at 5 × 103 cells per well. Cells were transfected 
with miRNA mimics or NC 18 to 24 hours after plating. Cell viability assays were 
performed by adding Alamar Blue (resazurin) reagent at 6.5 μg/ml and incubated for 30 
min at 37°C. Converted resafurin fluorescence was measured at λEx/λEm 590 nm using a 
Fluostar Optima plate reader. Cell viability was normalized to control transfected cells. 
For caspase-3 activity–based apoptosis assays, cells were plated in white 96-well plates 
and transfected with miRNA mimics, as described above. Caspase-3 activity was 
measured using the luminescence-based Caspase-Glo 3/7 assay (Promega Inc.) 48 hours 
after transfection, by directly adding 25 μl of the caspase assay mix to cells. 
Luminescence was measured using a Fluostar Optima plate reader, with a 10-s 
integration time. For p62 and beclin 1 rescue experiments, cells were transduced with 
GFP-p62 (pMXs-puro GFP-p62 was a gift from N. Mizushima, Addgene plasmid 
#38277) or pLEX-BECN1. Stable polyclonal cell populations were selected in puromycin 




transfected with miR-124 or NC at 50 nM. After 72 hours, cell viability was assessed 
using the Alamar Blue assay as described above. 
Clonogenic and Matrigel assays 
 For clonogenic assays, 5 × 103 cells were plated in six-well plates and transduced 
with control or miR-124 lentiviral vectors. Transduced cells were plated at 500 cells per 
60-mm dish. Clones were grown for 2 weeks, fixed in EM (electron microscopy)–grade 
4% formaldehyde, and stained with Giemsa dye according to the manufacturer’s 
guidelines. For 3D clonogenic growth assays in Matrigel, control or miR-124–transduced 
cells were plated in eight-well chamber slides (NUNC Inc.) using a bottom layer “on-top” 
method, as described previously [291]. Colonies were allowed to form for 2 weeks with 
media change every alternate day. Colonies were imaged by bright-field microscopy, and 
CellProfiler software [292] was used to determine colony counts and size. Colonies were 
fixed in EM-grade 4% formaldehyde and stained with DAPI and phalloidin. For cleaved 
caspase detection, colonies were permeabilized with 0.1% Triton X-100 and incubated 
with cleaved caspase-3 primary antibody (Cell Signaling Inc.) overnight. Anti-rabbit 
secondary antibody–conjugated to Alexa 594 was used for immunofluorescence 
detection. Images were acquired with a Cytation 3 imaging system (BioTek Inc.) 
equipped with 10× objective lens. Raw tif files were processed in Adobe Photoshop to 





 Cells were fixed in 4% EM-grade formaldehyde and permeabilized with 0.1% 
Triton X-100. Cells were stained with primary antibodies against vimentin, E-cadherin, 
and p62 overnight at 4°C followed by fluorescent-labeled Alexa 488– or Alexa 594–
conjugated goat anti-mouse/anti-rabbit secondary antibodies (Molecular Probes). 
Spheroids in Matrigel were fixed as described previously [291] and stained with Alexa 
594–conjugated phalloidin to stain actin filaments (Thermo Fisher Scientific); DAPI or 
Hoechst 33256 dyes were used to stain nuclear DNA. Leica SP5 Laser Confocal 
Microscope equipped with a 63× oil objective (Fig. 3.3B) was used for image acquisition. 
Micrographs shown in Fig. 3.1E were captured on an Olympus IX81 Spinning Disk 
Deconvolution Microscope equipped with a 40× Plan-Apo oil objective lens. Digital 
images were processed with SlideBook. Images were compiled and further processed 
with NIH ImageJ, Adobe Illustrator, and Photoshop CS6. 
Western blotting and antibodies 
 Protein lysates were prepared with 1× Laemmlli buffer followed by 15-s pulse 
sonication. Lysates were normalized for total protein content using bicinchoninic acid 
assay reagent (Pierce-Thermo). Proteins were separated by SDS–polyacrylamide gel 
electrophoresis followed by transfer to polyvinylidene difluoride membranes. Enhanced 
chemiluminescence (ECL) was performed with West-Pico or West-Dura reagents 
(Pierce-Thermo). The Syngene G-Box XT4 system and Genesys software were used for 
ECL imaging. The following antibodies were used for Western blotting: cleaved PARP 




1:1000), vimentin, phospho-S6, t-S6, beclin 1, Atg16L1, p62/Sqstm1, LC3-I/II, 
p65/NFkB1, NBR1 (Cell Signaling, 1:1000), and GAPDH (Santa Cruz, 1:5000). All 
antibodies were diluted in 2% BSA (bovine serum albumin)/TBS-T (tris-buffered saline 
with Tween 20) solution. 
Live-cell imaging of autophagy 
 Cells stably expressing dual-reporter pBabe-puro mCherry-EGFP-LC3B [257] 
were plated at 5 × 103 density in a 12-well plate format in phenol red–free RPMI 
1640/5% FBS. Twenty-four hours after seeding, cells were transfected with miR-124 or 
NC oligos. Six hours after transfection, these cells were treated with 50 μM chloroquine. 
Live cells maintained at 37°C and 5% CO2 were imaged in a Cytation 3 imaging system 
(BioTek Inc.) equipped with 10× objective lens for 72 hours. Nine fields per well were 
selected, and images were taken every 20 min using laser autofocusing. GFP or mCherry 
fluorescence was imaged using light-emitting diode filter cubes with λEx/λEm 469/525 
nm and 586/647 nm, respectively. Gen5 imaging software was used to identify and 
quantitate green and red LC3 puncta by setting empirically derived thresholds. 
Fluorescence intensity cutoffs were established to specifically count green/red puncta 
(autophagosomes/APs) or red puncta alone (autolysosomes/ALs). 
miRNA isolation and measurement 
 Total RNA from cells was isolated using the miRNeasy mini kit (Qiagen) 
according to the manufacturer’s guidelines. Total RNA (1 μg) was transcribed to cDNA 




miScript primer assays (Qiagen). Relative expression levels of mature miRNA were 
analyzed by real-time qPCR in a StepOne Plus system (Applied Biosystems Inc.). U6 
small nuclear RNA was used as an endogenous small RNA control for miRNA 
normalization, and relative expression levels of miRNAs were calculated using the 
2−ΔΔCt method after normalization [293]. 
Cytokine expression array analyses 
 Cells (1 × 106) were plated in RPMI/0.5% FBS in 150-mm dishes. After 24 
hours, cells were transfected with 50 nM control or miR-124 mimic. Forty-eight hours 
after transfection, conditioned media were collected and concentrated 20-fold with 3-kDa 
centrifugal filter units (Millipore). Concentrated media were applied to human 
inflammation antibody array C3 (Ray Biotech Inc.) to detect cytokines according to the 
manufacturer’s guidelines. Antibody binding was visualized and quantitated by ECL with 
the Syngene G-Box XT4 system/GeneSys software. Data analysis was performed using 
NIH ImageJ and a dot blot analyzer plug-in. Dot intensity data were normalized and 
processed in Microsoft Excel. 
Statistical analyses 
 Statistical and computational analyses were performed using “R” or GraphPad 
Prism. Analyses were verified and validated by C.-T. Liu (Department of Biostatistics, 
Boston University School of Public Health). For parametric tests on normally distributed 
data, we performed Student’s two-sided t tests assuming unequal variances. Colony size 




indicated, **P < 0.01 and ***P < 0.001. For correlation analyses of gene expression 
microarray data derived from primary tumors in NSCLC patients (NIH/GEO accession 
number GSE43458), RMA normalized data were generated in R, and individual gene-
level data for MIR124, MIR200C (primary transcripts), BECN1, and TRAF6 were 
extracted. Pearson correlation coefficients and associated P values for pairwise gene 
expression comparisons were calculated in R using cor.test. Scatter plots were generated 
with the ggplot package in R. 
Results 
KE versus KM subtypes are distinguished by a miRNA expression signature 
 Preliminary computational analysis of a previously derived KE/KM gene 
expression signature [31] using the Oncomine Concepts Map showed significant overlap 
with predicted target genes for miR-205 (odds ratio, 4.48; P = 0.002) and miR-34b/c 
(odds ratio, 3.65; P = 0.002). The role of miR-205 in modulating EMT and the role of 
miR-34 in the p53 pathway provided rationale to investigate altered miRNA expression 
and function in the context of KRAS dependency and EMT subtype–associated 
phenotypes. To that end, we performed quantitative reverse transcription polymerase 
chain reaction (qRT-PCR) TaqMan Low-Density Array (TLDA) assays to determine 
expression levels of 380 well-annotated mature miRNAs in a panel of six representative 
KRAS mutant NSCLC cell lines (Fig. 3.1). First, to identify differentially expressed 
miRNAs in KE versus KM subtype cells, we performed Student’s two-sided t tests on 
normalized average ΔCt values (threshold cycle method) assuming unequal variances 




differences comparing average ΔCt values for each subtype. We found that KE-correlated 
miRNAs were moderately higher in total number than KM-correlated miRNAs (160 
versus 120, respectively) (Fig. 3.1A). 
 To select differentially expressed miRNAs, we set a slightly liberal threshold (t 
test–derived P < 0.1), given the low sample size (n = 6) and our overarching goal of 
identifying miRNAs for subsequent functional studies of tumor suppressor activity. This 
led to the identification of 30 miRNAs that met the threshold criteria, 9 of which are 
correlated with KM cell lines compared to 21 KE-correlated miRNAs. To visualize 
coclustered miRNA expression patterns, hierarchical clustering was performed to 
generate a heat map of differentially expressed miRNAs (Fig. 3.1B). Notably, miR-200c 
and miR-141, which are expressed as a tandem primary RNA transcript from a locus on 
chromosome 12p13.31, were coclustered, indicating concordant expression patterns. We 
identified miR-205 as KE-correlated, validating the initial Oncomine analysis. We then 
determined whether the expression of a select panel of KE-associated miRNAs was 
regulated by oncogenic KRAS. In H358 KE cells, small interfering RNA (siRNA)–
mediated depletion of KRAS reduced the abundance of specific KE-correlated miRNAs 
(miR-124, miR-200c, miR-141, miR-199, and miR-625). However, in a different KE cell 
line (H2009), only miR-124 and miR-200c levels were reduced after KRAS depletion, 
whereas the others were up-regulated. Therefore, one could surmise that KRAS promotes 
the proliferative phenotype in epithelial cells at least in part by supporting the expression 




in the KRAS mutant mesenchymal cells and which signaling mechanisms modulate the 
other EMT-associated miRNAs remain to be determined. 
 Members of the miR-200 family and miR-205 regulate EMT [287], and 
expectedly, their increased expression in KE cells and decreased expression in KM cells 
correlated with the abundance of epithelial and mesenchymal markers, respectively (Fig. 
3.1C). To validate a causal role for miR-205 and miR-200c in regulating EMT in these 
KRAS mutant NSCLC lines, we performed synthetic miRNA oligonucleotide mimic 
transfection assays in representative KM cell lines. In H460 cells, reconstitution of miR-
205 and miR-200c resulted in repression of an established target, Zeb1 (Fig. 3.1D). Zeb1 
is a C2H2-type zinc-finger protein that functions as a transcriptional repressor of the 
CDH1 locus, resulting in reduced abundance of epithelial E-cadherin protein, 
mesenchymal differentiation, and cancer stem cell–like phenotypes [294]. Suppression of 
Zeb1 abundance by miR-200c and miR-205 was associated with increased E-cadherin 
protein abundance. miR-200c reconstitution caused slightly higher E-cadherin protein 
induction compared to miR-205 reconstitution. Expression of the mesenchymal marker 
vimentin was reduced slightly upon reconstitution of high concentrations of miR-200c 
(Fig. 3.1D). Compared to H460 cells, A549 cells had a greater amount of E-cadherin 
under control conditions, which increased moderately with miR-200c or miR-205 
reconstitution and was associated with decreased abundance of Zeb1 protein. KE-
correlated miRNAs did not broadly alter E-cadherin abundance in H460 KM cells; only 
miR-200c and miR-141 caused appreciable increases in E-cadherin protein abundance. 




punctate structures in control cells to more pronounced localization at cell-cell contacts in 
miR-200c–reconstituted cells (Fig. 3.1E). This phenotype is very similar to direct Zeb1 
ablation by shRNA in KM cells [31]. Finally, we validated a positive correlation (r = 
0.476; P = 1.12 × 10−6) between expression levels of MIR200C and MIR124 primary 
RNA transcripts in a microarray data set derived from primary tumors in NSCLC patients 
[National Institutes of Health (NIH)/Gene Expression Omnibus (GEO) accession number 
GSE43458] [295]. In summary, a comparison of KE and KM miRNA expression profiles 







Figure 3.1. KRAS oncogene dependency and epithelial-mesenchymal phenotypes are associated with a miRNA 
expression signature in NSCLC cell lines. 
(A) Volcano plot of differential miRNA expression based on quantitative PCR (qPCR)–based profiling in six 
representative KRAS mutant NSCLC cell lines. Fold expression differences were calculated by comparing average 
expression levels in three KRAS-dependent/epithelial (KE-correlated) cell lines to three KRAS-
independent/mesenchymal (KM-correlated) cell lines. Student’s t test–derived P values are plotted on a −log scale on 
the horizontal axis (two-sided test with unequal variances). (B) Heat map representation of differential miRNA 
expression levels (P < 0.1) in KE versus KM subtype cell lines, as used in the volcano plot in (A). Orange and purple 
indicate high and low median-centered expression levels, respectively. Cell lines and miRNAs are clustered by 
similarity as determined by Euclidean distance. (C) Western blotting for abundance of epithelial markers (P-cadherin, 
E-cadherin, and b-catenin) and vimentin as a mesenchymal marker in a panel of KM (red text) and KE (green text) 
NSCLC cell lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serves as a gel loading control for (D) and 
(E). (D) Western blot showing effects of miR-200c and miR-205 reconstitution in H460 KM cells at two concentrations 
of synthetic mimic oligonucleotides (10 and 50 nM) on the abundance of epithelial and mesenchymal markers. Data are 
representative of two independent experiments. (E) Confocal immunofluorescence micrographs of H460 cells 
transfected with control or miR-200c mimics. Cells are shown costained with E-cadherin (green channel) and vimentin 





A subset of KE-correlated miRNAs causes reduced cell viability in KM cell lines 
 We selected a panel of 22 differentially expressed KE-correlated miRNAs based 
on highest fold difference from the analyses described in Fig. 3.1. To determine potential 
tumor suppressor activities of identified miRNAs, we performed comprehensive 
functional cell viability assays after reconstitution of KE-correlated miRNA mimics in a 
test set of six KM cell lines [31]. We performed synthetic miRNA mimic oligonucleotide 
transfections and assessed cell viability effects 72 hours later [296]. We noted 
significantly reduced cell viability after reconstitution of a number of miRNAs compared 
to control transfection, which varied across the cell lines tested (Fig. 3.2A). From this 
analysis, we qualitatively determined that miR-124 had generally negative effects on cell 
viability in all the cell lines tested. SW900 and H460 cells were generally more sensitive 
to the cytotoxic effects of KE-correlated miRNA reconstitutions than the other cell lines 
tested. 
 Next, we performed hierarchical clustering analysis of normalized cell viability 
data and generated a heat map (Fig. 3.2B). Cell lines could be coclustered by similarity of 
responses to miRNA reconstitution, with H1792 and SK-LU-1 cells showing the most 
concordant sensitivity patterns. H2030 and LU65 cells also showed a similar degree of 
concordance. We noted some cell line–specific effects, including sensitivity to miR-210 
in LU65 and SW900 cells. Notably, we found that miR-205 caused minimal cell viability 
effects in all the cell lines tested, despite being the most significantly overexpressed 
miRNA in the KE subtype. In addition, miR-146b-5p and miR-125b failed to induce cell 




viability in all cell lines tested: miR-124, miR-518d-3p, and miR-625. Of these, miR-124 
had the most potent effects on reducing cell viability in all KM cell lines. 
 
Figure 3.2. Reconstitution of specific KE-correlated miRNAs causes reduced cell viability in KM cell lines. 
(A) Alamar Blue–based cell proliferation/viability assays measuring relative viability of indicated cell lines after 
transfection with 10 nM synthetic miRNA mimic oligonucleotides compared to NC-transfected cells 72 hours after 
transfection. Data are means of three replicates ± SEM. Viability effects of miR-124 are highlighted with a red asterisk. 
(B) Heat map representing normalized mediancentered viability data from (A). Cell lines and miRNAs are clustered by 





miR-124 reconstitution induces apoptosis and suppresses clonogenic growth of KM cell 
lines 
 To further elucidate cytotoxic mechanisms caused by reconstitution of KE-
correlated miRNAs in KM cell lines, we used a luminescent caspase-3–Glo reporter 
assay to measure effects on apoptosis. Increased luminescence in this assay is 
proportional to increased effector caspase-3 activation. We tested three miRNAs (miR-
124, miR-199a, and miR-625), which all caused increased caspase-3 activation in H460 
KM cells (Fig. 3.3A). Of these, miR-124 caused the strongest caspase-3 activation 
compared to miR-199a and miR-625. In contrast, caspase-3 activity was weakly induced 
or absent in KRAS wild-type H322 NSCLC cells and MCF7 breast cancer cells (Fig. 
3.3A). 
 Given that, among the KE signature miRNAs tested, miR-124 had the greatest 
cytotoxic effects in KM cells, we focused our subsequent efforts on investigating miR-
124. To determine whether the cytotoxic effects of miR-124 conferred reduced 
clonogenic growth, we transduced A549 KM cells with a lentiviral vector encoding the 
primary form of miR-124 (pri-MIR124). The MCF7 breast cancer cell line, which again 
have wild-type KRAS, was transduced alongside as a control. We then performed culture 
assays of stable cell lines in Matrigel. A549 cells expressing miR-124, when grown in 
Matrigel, displayed signs of cytotoxicity manifesting as reduced size and number of 
colonies (Fig. 3.3, B and C). Furthermore, nuclear DNA fragmentation indicative of cell 
death could be observed in many of the miR-124–expressing cells (Fig. 3.3B). In contrast 




expressing miR-124. Reconstitution of miR-124 in H460 cells caused increased caspase-
3 cleavage in 3D cultures, as determined by immunofluorescence microscopy, and 
reduced clonogenic growth in monolayer cultures. Finally, miR-124–mediated 
cytotoxicity was associated with distinct morphological features, including the 
appearance of dense intracellular vacuolar structures (Fig. 3.3D). This indicated a 
possible perturbation of lysosomal function, perhaps as a consequence of altered 
regulation of macroautophagy, referred to hereafter as autophagy. Constitutive activation 
of the cytoprotective autophagy pathway drives survival in subsets of KRAS mutant 
mesenchymal-like cancer cell lines [297]. This prompted our interest in investigating a 







Figure 3.3. miR-124 reconstitution causes cytotoxic effects in KM cell lines. 
(A) Luciferase-based caspase-3 activation assays after reconstitution of indicated miRNA mimics in H460KM cells, 
H322 KRAS-WT NSCLC cells, andMCF7 KRAS-WT breast cancer cells. (B) Three-dimensional (3D) Matrigel assays 
of A549 KM cell growth after lentiviral expression of control luciferase or primary MIR124 (pri-MIR124). Fixed cells 
are shown stained with phalloidin to visualize actin filaments (red signal) and 4′,6-diamidino-2-phenylindole (DAPI) to 
visualize nuclear DNA (blue signal). Arrow indicates an apoptotic cell with fragmentedDNA and low actin content. 
Scale bars, 25 mm. (C) Automated image-based quantitation of colony size and number from 3D Matrigel assays 
shown in (B). Colony size is in arbitrary pixel units. Bars represent population means ± SEM. (D) Bright-field 
microscopy images of NC- or miRNA-transfected cells. Arrows indicate large intracellular endosomal, possibly 





miR-124 reconstitution causes autolysosomal maturation defects in KM cells 
 A number of assays and guidelines have been developed and established to study 
activation of autophagy and so-called “flux” through the pathway [298]. To monitor 
autophagy flux in cells reconstituted with miR-124, we used a common dual fluorescent 
LC3 reporter, which is expressed as an N-terminal fusion of mCherry and green 
fluorescent protein (GFP) to human LC3B (Fig. 3.4A) [257]. Activation or inhibition of 
the autophagy pathway is determined by quantitating LC3 aggregates by live-cell 
fluorescence microscopy. Overlap of red and green signals from mCherry and GFP, 
respectively, will appear as yellow aggregates upon induction of phagophore formation 
and autophagosome (AP) accumulation. If the autophagy pathway is in flux, then these 
yellow aggregates will be transient as APs fuse with acidic lysosomes to form 
autolysosomes (AL) in which the low pH quenches GFP fluorescence, resulting in rapid 
accumulation of dense red aggregates (Fig. 3.4A). 
 We introduced mCherry-GFP-LC3 (mCG-LC3) into H460 cells by stable 
retroviral transduction to monitor LC3 dynamics in live cells in real time. These cells 
were transfected with miR-124 mimics either alone or in combination with the 
lysosomotropic agent hydroxychloroquine (chloroquine), which causes rapid 
deacidification of lysosomes and a subsequent block in autophagosome/lysosome fusion. 
Live-cell imaging of mCG-LC3 aggregates over 72 hours after the addition of agents to 
H460 cells revealed dynamic alterations in autophagy flux induced by miR-124 and/or 
chloroquine compared to control cells (Fig. 3.4B). In control cells, some green/yellow AP 




density increased over 48 to 50 hours, red AL aggregates began to form and accumulate 
(Fig. 3.4B, first row). In miR-124–reconstituted cells, overall GFP fluorescence was 
weak, but yellow AP aggregates began to form around 22 hours after transfection (Fig. 
3.4B, second row). Notably, the AP aggregates appeared as single large aggregates per 
cell. These aggregates persisted for an additional 8 to 20 hours and eventually dissipated. 
Cells with accumulated AP aggregates underwent cell death at 48 to 50 hours after 
transfection. Chloroquine treatment caused formation and accumulation of dense AP 
aggregates, as expected based on previous reports (Fig. 3.4B, third row) [299]. 
Chloroquine-induced AP aggregates persisted for 50 hours, with some undergoing mild 
AL maturation. The AP aggregates in chloroquine-treated cells were more numerous and 
smaller per cell, in contrast to miR-124–reconstituted cells. Chloroquine treatment alone 
had mild cytotoxic effects in H460 cells. When combined with miR-124 reconstitution, 
chloroquine promoted synergistic cell death (Fig. 3.4B). 
 We performed software-based image cytometry and set thresholds to identify and 
count LC3 aggregates based on size and fluorescence intensity. AP and AL puncta were 
identified by setting appropriate empirically derived thresholds for mCherry and GFP 
fluorescence. To increase the accuracy of puncta identification and quantification, 
“gating” was performed to isolate high green and high red fluorescent AP puncta in 
contrast to low green and high red fluorescent AL puncta. In control cells, AP counts 
remained at a steady-state low level (Fig. 3.4C). miR-124 reconstitution caused a mild 
increase in AP counts, whereas chloroquine treatment caused a significant steady time-




AL maturation. Chloroquine-treated cells showed accumulation of multiple APs per cell. 
In contrast, in miR-124–reconstituted cells, chloroquine-induced AP accumulation was 
severely blunted about 10 hours after transfection. Control cells showed robust AL 
accumulation over time, consistent with constitutive basal activation of autophagic flux in 
these cells. Reconstitution of miR-124 caused a noticeable effect on blocking AL 
accumulation (Fig. 3.4D). This latter effect on blocking AL formation by miR-124 was 
comparable to the effects of chloroquine. This effect of miR-124 on blocking AL 
accumulation was additive when combined with chloroquine (Fig. 3.4D). Calculation of 
AL/AP ratios further demonstrated relatively high AL accumulation in control cells, 
which was severely impaired in chloroquine-treated cells and moderately impaired in 
miR-124–transfected cells (Fig. 3.4E). In summary, miR-124 causes defects in AP 
maturation and AL accumulation in H460 KM cells. mir-124 combined with chloroquine 
causes enhanced blockade of AP and AL accumulation, which is accompanied by 





Figure 3.4. miR-124 reconstitution blocks autolysosome accumulation in KM cells. 
(A) Schematic overview of the mCherry-GFP-LC3 reporter. (B) Live-cell imaging of H460 KMcells expressing 
themCherry-GFP-LC3 reporter and transfected with miR-124 oligonucleotide dsRNA and/or treated with 50 mM 
chloroquine. Arrows indicate LC3 aggregates that are GFP and mCherry double-positive, indicative of phagophore or 
autophagosome accumulation. Time is shown in hours. Scale bars, 25 mm. (C) Quantitation of GFP/mCherry double-
positive puncta, indicating phagophores/autophagosomes (AP) using image analysis software (BioTek Gen5). (D) 
Quantitation of mCherry-positive autolysosomes (AL). (E) Quantitation of AL/AP ratio. Data are representative of 





miR-124 suppresses p62 and beclin 1 abundance selectivity in KM cells 
 To determine mechanisms underlying miR-124–mediated regulation of the 
autophagy pathway, we analyzed the abundance of key autophagy pathway protein 
components after miR-124 reconstitution, including SQSTM1/p62 and LC3-I/II, which 
are well-established markers of pathway activation [265]. First, we validated that 
reconstitution of miR-124 induced apoptosis in all KM cell lines tested, as assessed by 
increased levels of cleaved poly(ADP-ribose) polymerase (PARP). Abundance of beclin 
1, which initiates phagophore formation and promotes autolysosome maturation [300, 
301], was suppressed in all four KM cell lines by reconstitution of miR-124 (Fig. 3.5A). 
We used the TargetScan web portal to identify a high-probability predicted target site for 
miR-124 in the 3′ untranslated region (3′UTR) of beclin1/BECN1 mRNA. We 
confirmed that miR-124 directly targets the 3′UTR of BECN1 using an engineered 
luciferase reporter construct whose luminescence was reduced 40% by miR-124 
reconstitution compared to control transfected cells, whereas miR-200c reconstitution 
failed to cause significant effects on reporter activity. Furthermore, exogenous expression 
of beclin 1 in A549 cells caused a mild 10% rescue of miR-124–dependent cell 
proliferation defects. Beclin 1 expression also partially rescued effects on PARP cleavage 
and LC3-II accumulation after miR-124 reconstitution. Finally, BECN1 and MIR124 
expression were inversely correlated in primary NSCLC tumor samples from patients (r = 
−0.44; P = 4.35 × 10−5). 
 Next, we found that miR-124 induced altered expression of ATG16L1, with 




associated with impaired AP maturation (Fig. 3.5A) [302]. In addition, miR-124 caused 
robust suppression of the selective autophagy adaptor protein p62. These effects of miR-
124 were associated with increased expression of LC3-II, indicating a block in AL 
function, because LC3-II degradation and turnover are mediated by AL activity. 
Furthermore, immunofluorescence microscopy of p62 expression showed that miR-124 
caused a significant reduction in the number and size of p62 aggregates in H460 cells. 
TargetScan analysis of the SQSTM1 3′UTR also showed a predicted miR-124 target 
seed sequence. The effects of miR-124 on the autophagy pathway correlated with 
reduced abundance of phosphorylated S6 at Ser235/236, indicating perturbation of 
mTOR/S6K or ERK (extracellular signal–regulated kinase)/RSK (ribosomal protein S6 
kinase) activity. Reduced SQSTM1 mRNA abundance upon miR-124 reconstitution was 
validated by qPCR. Reduced p62 abundance is usually associated with an increased 
rather than a decreased autophagic flux. We suggest that miR-124 blocks AP formation 
and maturation via suppression of beclin 1, concomitant with suppression of p62 
abundance. 
 To provide further supportive evidence for a role of miR-124 in blocking 
autolysosome formation and function, we analyzed expression levels of another selective 
autophagy adaptor protein, NBR1, which is involved in selective autophagic degradation 
of some ubiquitinated cargo proteins [303]. Reconstitution of miR-124 caused increased 
NBR1 protein abundance in a panel of KM cell lines. This was associated with increased 
LC3-II levels, indicative of reduced AL function, consistent with the aforementioned data 




investigated the effects of combining chloroquine with miR-124 reconstitution on NBR1 
protein levels in H460 cells (Fig. 3.5B). Chloroquine treatment caused increased p62 
protein levels, consistent with a block in AL function. This effect was abrogated by 
combined reconstitution of miR-124 with chloroquine treatment. Under the same 
conditions, NBR1 abundance was additively increased. Surprisingly, we found that 
chloroquine treatment alone did not promote an increase in the amount of NBR1. The 
reasons for this are unclear, given that p62 protein abundance was markedly greater in 
chloroquine-treated cells. Nonetheless, the findings indicate that miR-124 inhibits 
selective autophagy by blocking autolysosome formation and function. 
 Given the sensitivity of mesenchymal cell lines to miR-124 reconstitution, we 
investigated a causal role for EMT in modulating this sensitivity. Whereas miR-124 
induces apoptosis in H460 KM cells, as assessed by increased abundance of cleaved 
PARP, there was no such apoptotic response in the KE H358 cell line (Fig. 3.5C). miR-
124 caused suppression of vimentin abundance in both H460 and H358 cells. On the 
basis of TargetScan analysis, the VIM mRNA (encoding vimentin) harbors a predicted 
miR-124 target site in the 3′UTR. Notably, p62 abundance was decreased only in H460 
KM cells but not in H358 KE cells (Fig. 3.5C). This could be due to additional p62 
regulatory mechanisms that are active in KM cells. 
 To establish a causal role for EMT in mediating sensitivity to miR-124 
reconstitution, we used a stable mesenchymal variant of the H358 cell line, designated as 
H358M [31]. In contrast to H358 cells, H358M cells were more sensitive to miR-124 




Gross morphological cytotoxicity could also be observed in miR-124–reconstituted 
H358M cells, which was not apparent with the parental H358 cells. As with H460 KM 
cells, miR-124 suppressed vimentin and p62 levels in H358M cells (Fig. 3.5D). The 
sensitivity of H358M cells to miR-124 was associated with decreased levels of mature 
miR-124 RNA levels in H358M compared to parental H358 cells (Fig. 3.5E). Finally, to 
determine whether miR-124 had cross-tissue effects on p62, we investigated the effects in 
KRAS mutant mesenchymal pancreatic ductal adenocarcinoma (PDAC) cell lines, KP1N 
and KP4. As with NSCLC KM cells, miR-200c caused increased E-cadherin expression 
in PDAC KM cells. mir-124 reconstitution caused p62 suppression in PDAC cell lines, 
similar to the effects in NSCLC cell lines. 
 In addition to p62, we identified other putative miR-124 target genes, including 
beclin 1 and vimentin, lending uncertainty to which target genes mediate the phenotypic 
effects of miR-124 in KM cells. Therefore, we determined whether miR-124 directly 
suppresses SQSTM1/p62 expression by binding the 3′UTR of p62 mRNA and whether 
this suppression was responsible for the cytotoxic effects observed in KM cell lines. First, 
we noted that H460 cells were sensitive to siRNA-mediated depletion of p62 as assessed 
by PARP cleavage–associated cell death, which was not evident in the H358 KE cell line. 
This indicates that p62 drives anti-apoptotic signaling in H460 and, possibly, other KM 
cell lines. Second, we performed a luciferase-based assay with a lentiviral reporter vector 
containing the entire 3′UTR of human SQSTM1 mRNA downstream of LUC/luciferase 
gene driven by an EF1α promoter (Fig. 3.5F). To functionally validate the predicted 




on reporter activity of either wild-type or mutated miR-124 target site seed sequences 
(Fig. 3.5F). Introduction of miR-124 resulted in a 50% reduction in the reporter gene 
activity of the SQSTM1 3′UTR containing wild-type miR-124–targeting sequences 
(Fig. 3.5F). In contrast, two different mutated SQSTM1 3′UTR sequences did not 
respond significantly to miR-124–mediated luciferase suppression. Last, we performed 
rescue experiments using exogenous expression of GFP-tagged p62 that lacks the 
endogenous SQSTM1 3′UTR sequence. Exogenous expression of GFP-p62, which is 
resistant to suppression by miR-124, rescued the cell viability defects caused by miR-124 
reconstitution in SW900 and A549 KM cell lines (Fig. 3.5G). In summary, we conclude 
that cytotoxic effects of miR-124 are selective for KM subtype cells via coordinated 
effects on the autophagy pathway and apoptosis induction, with p62 as a central hub in 





Figure 3.5. miR-124 reconstitution represses beclin 1 and p62 expression selectively in KM cells. 
(A) Western blot showing protein expression levels of cleaved PARP, indicative of apoptosis, and autophagy pathway 
components beclin 1, ATG16L1 a/b splice isoforms, p62, and LC3-I/II after transfection with miR-124 in two KRAS 
wild-type (WT) cell lines (MCF7 and H322) and four KM cell lines. GAPDH is a gel loading control. (B) Western blot 
analysis of effects of miR-124 transfection minus/plus chloroquine treatment on expression levels of p62, NBR1, and 
LC3-II in H460 cells. (C) Western blot showing indicated protein levels after miR-124 reconstitution in H460 KM cells 
compared to H358 KE cells. Cleaved (D) PARP indicates apoptosis. E-cadherin and vimentin indicate epithelial versus 
mesenchymal differentiation. (D) Western blot analysis of cleaved PARP, E-cadherin, vimentin, and p62 in H358 KE 
cells compared to a stable mesenchymal derivative cell line H358M after miR-124 transfection. GAPDH serves as a gel 
loading control for (A) to (C) and (F). (E) Quantitation of endogenous mature miR-124 levels by qPCR in H358M cells 
relative to parental H358 cells. **P < 0.005. (F) Schematic representation of the human p62/SQSTM1 3′UTR showing 
the miR-124 binding site seed sequence and point mutants (1 and 2) that disrupt the miR-124/ SQSTM1 interaction. 
Reporter activity of WT or mutant SQSTM1 3′UTRs after miR-124 transfection. Data are means of three replicates + 
SEM. ***P < 0.0005; n.s., not significant. (G) Rescue of miR-124–induced cell viability defects with exogenous GFP-
tagged p62 expression in A549 and SW900 KM cell lines. Data are means of three replicates ± SEM. **P < 0.005. All 




NF-κB signaling and cytokine expression are regulated by miR-124 
 In addition to a role in autophagy, p62 is critical for activation of the nuclear 
factor–κB (NF-κB) transcriptional complex and downstream effects on inflammatory 
cytokine signaling [304]. We found that expression of the p65 subunit (NFKB1/RELA) 
of NF-κB was suppressed after miR-124 reconstitution. This was accompanied by 
reduced abundance of the E3 ubiquitin ligase TRAF6, which mediates IκB kinase (IKK) 
and subsequent NF-κB activation (Fig. 3.6A) [305]. The TargetScan portal returns 
TRAF6 and p65/RELA as predicted miR-124 target genes. Furthermore, TRAF6 and 
MIR124 mRNA abundance were inversely correlated in primary NSCLC samples (r = 
−0.62; P = 8.45 × 10−10). We verified that miR-124 caused reduced NF-κB signaling by 
using a κB binding element–firefly luciferase construct. In A549 and SW900 KM cells, 
we observed twofold to threefold decreases in NF-κB transcriptional activity after miR-
124 reconstitution (Fig. 3.6B). 
 Given the role of NF-κB in regulating inflammatory cytokine signaling, we 
hypothesized that cytokine expression levels might be altered in miR-124–reconstituted 
KM cells. Conditioned media from miR-124–reconstituted KM cells contained altered 
levels of key cytokines compared to nontarget control (NC)–transfected cells (Fig. 3.6C). 
Quantitation of cytokine levels revealed that proinflammatory cytokines, such as tumor 
necrosis factor–α (TNFα) and interleukin-1α (IL-1α), were increased upon miR-124 
reconstitution in KM cells. Other induced factors included transforming growth factor–β, 
IL-12, RANTES, IL-11, interferon-γ, and IL-6 (Fig. 3.6C). Conversely, GMCSF 




receptor (sTNFRI/II) were decreased upon miR-124 reconstitution. We verified that 
alterations in cytokine expression upon miR-124 reconstitution occurred because of 
changes in mRNA levels of key cytokines as assessed by qRT-PCR in the miR-124–
reconstituted KM cells. We noted strong mRNA induction of IL1B, IL11, and TNF, but 
surprisingly saw reduced IL6 expression. In summary, miR-124 reconstitution promotes 
suppression of TRAF6–NF-κB signaling and associated perturbations in pro- and anti-
inflammatory cytokine expression levels. 
 
Figure 3.6. miR-124 reconstitution induces an altered expression of NF-kB–regulated inflammatory cytokines. 
(A) Western blots showing protein expression levels of the p65 (RELA) subunit of NF-kB and TRAF6 after miR-124 
reconstitution in the indicated KM cell lines. GAPDH is a gel loading control. (B) NF-kB–dependent luciferase reporter 
assays showing arbitrary luminescence counts after control NC or miR-124 transfection in A549 and SW900 KM cells. 
***P < 0.0005, **P < 0.005. (C) Antibody-based proteomics array showing expression levels of inflammatory 
cytokines in conditionedmedia from NC ormiR-124–transfected H460 KM cells.Most significantly altered cytokines 
are highlighted in boxes. (D) Relative quantitation of pixel density from arrays shown in (C), comparing miR-124– to 





 Here, a KE/KM subtype miRNA signature was derived by differential miRNA 
expression profiling. The signature reveals EMT regulatory miRNAs, such as miR-205 
and miR-200c, and a number of cytotoxic miRNAs such as miR-124, which are 
expressed at significantly lower levels in KM cell lines compared to KE cell lines. We 
demonstrate that miR-124 negatively regulates cell viability in several KM cell lines 
upon functional reconstitution. Induction of cell death upon miR-124 reconstitution is 
associated with the formation of dense vacuolar structures, suggesting perturbations in 
lysosomal turnover and possible defects in autophagy. Autophagy is constitutively 
activated in subsets of KRAS mutant cancers and cell lines in large part via 
transcriptional mechanisms [138]. This is associated with maintenance of cell viability, 
suggesting a possible therapeutic vulnerability in KRAS mutant cancers [306]. Our 
findings indicate that KRAS mutant cells with mesenchymal differentiation exhibit 
constitutive flux through the autophagy pathway and are particularly sensitive to 
perturbation of this flux, for example, via reconstitution of miR-124. 
 Selective autophagy is promoted by beclin 1, and a specific cargo is targeted for 
degradation by the adapter protein sequestosome1/p62 [307, 308]. We conclude that 
suppression of beclin 1 and p62 by miR-124 is associated with defective AL maturation 
and accumulation. The defect in AL formation caused by miR-124 is supported by three 
independent experimental observations. First, miR-124 reconstitution prevents AL 
accumulation, as demonstrated by live-cell imaging of the fluorescent mCherry-GFP-LC3 




indicating a defect in AL function, which normally promotes LC3 degradation and 
turnover. Last, levels of another selective autophagy adaptor NBR1 accumulate after 
miR-124 reconstitution. NBR1 is critical for turnover of a number of ubiquitinated target 
proteins via autolysosomal degradation [303]. 
 Concomitant with perturbation of AL accumulation, suppression of p62 leads to 
cell death in KM cell lines. This observation is concordant with previous studies that 
demonstrate a role for p62 in mutant RAS-driven tumor maintenance [309]. The 
mechanisms by which p62 promotes the survival of KM cell lines is complex and may 
involve coordinated control of selective autophagy and activation of the NF-κB pathway. 
P62 binds to cargo targeted for degradation via the selective autophagy pathway, which 
includes ubiquitinated proteins and damaged organelles [265, 308, 310]. We also 
implicate beclin 1 as a key miR-124 target. We hypothesize that miR-124–dependent 
suppression of beclin 1 causes defects in the formation of mature ALs, which partially 
contributes to cytotoxic effects. Our findings support the notion that autophagy activation 
in KRAS mutant mesenchymal cancer cells plays a protumorigenic role. These findings 
contrast with studies indicating tumor suppressor roles for the autophagy pathway, as 
demonstrated by a tumor predisposition phenotype in mice with Becn1 heterozygous loss 
[311]. Context and molecular subtype dependence of oncogenic versus tumor suppressor 
roles for the autophagy pathway is a contentious issue and will need to be reconciled for 
the design and clinical use of autophagy inhibitors. 
 Our findings on the role of miR-124 in autophagy regulation are reinforced by 




in a number of autophagy-lysosomal pathway genes [312]. In addition to targeting of 
p62, as well as beclin 1, we found that miR-124 targets vimentin expression, which is an 
established mesenchymal cell marker protein. Studies show that vimentin can regulate 
autophagy by tethering an inhibitory AKT-phosphorylated beclin 1 in complex with 14-
3-3 protein [313]. Thus, miR-124 inhibits multiple steps in the autophagy pathway. Of all 
the putative miR-124 targets, our results strongly implicate SQSTM1/p62 as the most 
critical gene for the maintenance of KM cell survival, as demonstrated by rescue 
experiments. 
 Reduced p62 levels are commonly associated with increased autophagy flux, 
which promotes p62 autolysosomal degradation [307]. We found that miR-124–
dependent suppression of p62 is associated with increased NBR1 and LC3-II levels and a 
decrease in AL accumulation, indicative of a block in autophagy. How can these findings 
be reconciled? We hypothesize that miR-124 disrupts the formation and enclosure of 
autophagosomes, as occurs after beclin 1 or Vps34/class III PI3K gene ablation [314]. 
When miR-124 is expressed, p62 levels are decreased perhaps via destabilization of 
SQSTM1/p62 mRNA. Beclin 1 also regulates AL maturation via sequestration of the 
negative autophagy regulator Rubicon [301]. Therefore, miR-124–dependent suppression 
of beclin 1 could cause AL maturation defects, leading to increased LC3-II and NBR1 
levels. The miR-124–dependent block in autophagy is seen selectively in KM cell lines, 
because miR-124 introduction into KRAS wild-type cells and H358 KE cells fails to 




dependency in KM subtype cells remains unclear and will be interesting to explore in 
future studies. 
 The effects of miR-124–mediated suppression of p62 on cell viability are likely to 
involve disruption of multiple pathways, including negative regulation of autophagic 
flux. A recent study indicates that loss of cell viability in A549 and H460 KM cell lines 
can be induced by combined disruption of autophagy and the oxidative pentose phosphate 
pathway. This latter pathway could be subject to perturbation by miR-124 as a 
mechanism underlying cell death induction [315]. Furthermore, loss of p62 function has 
been linked to metabolic disruption in some contexts [316]. Therefore, metabolic 
reprogramming could be a mechanism to explain the cytotoxic effects of miR-124 
reconstitution in KM cells, which will be an interesting avenue to explore in future 
studies. 
 In addition to functioning as a selective autophagy adaptor, p62 regulates 
inflammatory signaling via IKK-dependent activation of the NF-κB pathway [309]. We 
show that miR-124 reconstitution promotes NFKB1/p65 suppression, leading to reduced 
NF-κB transcriptional activity and altered expression of key cytokines. This is consistent 
with a previous study identifying miR-124 as the top negative regulator of NF-κB in a 
miRNA mimic functional screen [317]. Whether this is a direct suppression of the p65 3
′UTR by miR-124 remains unclear. Mechanistic associations between activation of 
autophagy and inflammatory responses have been documented. For example, pathogenic 
antigen phagocytosis in macrophages is associated with increased LC3 aggregation on 




ATG16L1 mutations are causally associated with increased intestinal inflammation seen 
in Crohn’s disease [318]. We found that miR-124 reconstitution induces differential 
expression of the ATG16L1α isoform, which could feed into regulation of inflammatory 
signaling. 
 KRAS/TP53 co-occurring mutations, reflective of the KE subtype, correlate with 
increased proinflammatory signaling, whereas KRAS/STK11 or KRAS/KEAP1 
mutations associate with increased anti-inflammatory signaling, for example, via 
constitutive activation of the Nrf2 antioxidant pathway [277]. Thus, activation of anti-
inflammatory signaling is generally observed in a subset of KM cells that harbor STK11 
and KEAP1 mutations such as A549 and H460 cells. Together, our studies have defined 
an NSCLC subtype–specific regulatory mechanism that controls the coordinated function 
of the autophagy and NF-κB signaling pathways, with p62 as a central and critical hub in 
the network (Fig. 3.7). From a therapeutic perspective, miRNA reconstitution is currently 
being tested in preclinical and early-phase clinical trial settings [319]. Thus, 
reconstitution of miR-124 and other KE-correlated miRNAs may prove beneficial for a 





Figure 3.7. A model of miR-124 activity in KRAS mutant mesenchymal (KM) cells. 
In KM cells, under basal conditions, the balance between cell survival and cell death is tightly regulated by autophagy 
and NF-kB signaling pathways. Upon miR-124 reconstitution in KM cells, abundance of SQSTM1/p62, BECN1, 
TRAF6, and RELA was suppressed, causing inhibition of autophagy flux and perturbation of NF-kB signaling. 




CHAPTER FOUR: DISCUSSION 
SYK inhibition and autophagy activation in cell growth 
 SYK is a primary factor in the activation of several growth pathways, including 
ERK, Akt, and mTOR and has been repeatedly associated with cancer cell survival in a 
wide array of hematopoietic cancers. But in solid tumors, the role of SYK is hazier. Many 
studies have shown that SYK expression is correlated with decreased invasiveness and 
metastasis in breast cancer and melanoma. In contrast, other studies have described 
defects in cancer cell growth when SYK is inhibited in breast, pancreatic, and lung cancer 
cells. 
 We found that the spleen tyrosine kinase is a potent activator of mTORC1 in 
pancreatic cancer cells. This is supported by findings in other studies describing mTOR 
activity regulation by SYK in cancers of hematopoietic lineage and adipocytes [183-186]. 
Inhibition of SYK in PDAC cells resulted in decreased cell growth, suppression of 
mTORC1 activity, and subsequent hyperactivation of autophagic flux. We hypothesized 
that inhibition of mTORC1 activation of anabolic pathways and disruption of autophagy 
homeostasis through the inhibition of SYK were the primary drivers of inhibited cell 
growth in the pancreatic cancer cells that we tested. 
 Autophagy is hyperactivated in PDAC via dysregulation of the MiT/TFE family 
of transcription factors[138]. Studies have shown that both activation and inhibition of 
the autophagy pathway have successfully decreased cell growth of cancer cell lines and 
mouse xenografts [136, 137]. As studies continue to delineate the complex role of 




supports tumor growth will be of utmost importance if we are to target autophagy 
therapeutically. 
 Pancreatic cancers have a high frequency of oncogenic KRAS mutation and 
consequently, many researchers have turned to RAF-MEK-ERK inhibition as an 
approach to target this pathway. But these inhibitors have had little success in the clinic 
and resistance to these inhibitors is common. Several recent studies observed that 
pancreatic cancer cells resistant to RAF/MEK/ERK inhibition were found to upregulate 
the autophagy pathway in response to inhibitor treatment and these cells became more 
dependent on autophagy for survival. Combining RAF/MEK/ERK inhibition with 
autophagy blockade resulted in synergistic anti-proliferative effects against the PDAC 
cell lines. They proposed that RAF/MEK/ERK inhibition increased PDAC cell 
dependence on autophagy for survival and the cells utilized autophagy as an escape 
mechanism to the loss of mitogenic signaling [142-144]. In addition, a phase 1 clinical 
study in melanoma combined the mTOR inhibitor temsirolimus and hydroxychloroquine 
and found good tolerance for the combination with significant antitumor activity [132]. 
The caveat is that hydroxychloroquine is a promiscuous inhibitor and has several effects 
outside of the autophagy pathway. But these findings lend credence to the hypothesis that 
combined mTOR and autophagy blockade could be an effective approach in the right 
context. 
 It is not outside the realm of possibility that the activation of autophagy in 
response to SYK inhibition could be serving a similar “resistance” role. In contrast to our 




causes cell growth arrest, the activation of autophagy may be mitigating the cellular 
response to the loss of SYK activity. Combining SYK inhibition or knockdown with 
Atg5/7 knockout or hydroxychloroquine would be a worthwhile experiment to test this 
hypothesis in the future. 
SYK and mTORC1 regulation 
 There is evidence that current mTOR inhibitors do not completely ablate mTOR 
activity and phosphorylation of the mTORC1 target 4EBP is especially resistant. SYK 
regulation of mTOR occurs upstream and may avoid this issue encountered with 
rapalogs. One question that remains unanswered is the mechanism by which SYK 
activates mTORC1. Our work, and studies conducted in hematopoietic cancers, have 
indicated that the MEK/ERK pathway and PI3K/Akt/TSC pathways are not involved in 
this mechanism. As two of the most important regulatory mechanisms of mTORC1 
function, that leaves us to wonder how SYK may be functioning to activate mTORC1. 
This suggests that the regulation of mTORC1 is through some unknown and potentially 
undiscovered pathway. If this is indeed the case, SYK inhibition in combination with 
MEK/ERK inhibition and potentially autophagy blockade could be a multifaceted 
approach to target multiple parallel survival pathways at once, reducing the likelihood of 
resistance. Further study is warranted and the identification of putative SYK targets 
through unbiased phosphoproteomics is one possible approach. 
 Analysis of the putative SYK kinase consensus sequence using PhosphoSitePlus 
has generated a potential list of phosphorylation targets that may mediate SYK activation 




and the GEF for these GTPases, RAL-GEF. This is interesting because the Ral-GAPs 
shows structural similarity to TSC1 and 2, which are known inhibitors of the mTORC1 
pathway. The RalA and RalB proteins are known to integrate mTOR and autophagy 
signaling [320] and could be potential mediators of SYK activation of mTORC1. 
KRAS-dependency, EMT, and autophagy 
 The KRAS dependency transcriptional signature is intimately linked to epithelial-
mesenchymal transition, as described by Singh et al. [31]. The transcriptional signature of 
KRAS-dependent lines remarkably resemble that of epithelial cells in contrast the the 
more mesenchymal signature of KRAS-independent lines. Moreover, this transcriptional 
signature has revealed regulators of cell survival in KRAS-dependent pancreatic, colon, 
and lung cancer cells [31, 87, 290]. SYK was one of the hits from this signature highly 
expressed in KRAS-dependent, epithelial-like cells. In our work, we showed that SYK 
suppressed autophagy activity through the activation of mTORC1 and the cytoplasmic 
retention of MITF. A previous study also showed that SYK depletion in epithelial-like 
cells led to a reduction in the epithelial marker E-cadherin [31]. Similarly, a miRNA 
signature for KRAS-mutant epithelial vs mesenchymal cells revealed high miR-124 
expression in epithelial-like cells. We showed that miR-124 suppressed autophagic flux 
by targeting the autophagosome cargo protein Sequestosome-1. miR-124 reconstitution in 
mesenchymal like cells also showed a role in inducing the epithelial phenotype by 
decreasing the mesenchymal marker vimentin.  
 These two transcriptional signatures revealed two top hits, SYK and miR-124 that 




cause a more epithelial-like phenotype. Altering autophagy through both SYK and miR-
124 cause defects in cell growth. These findings suggest that autophagy is a vital pathway 
in KRAS-mutant cancer cells and that epithelial-like KRAS-mutant cells have several 
pathways at work that suppress it. These finding also suggest that autophagy, EMT, and 
KRAS-dependency may be more closely linked that we originally anticipated and further 
study of the hits of these two transcriptional signatures may reveal other regulators of 
autophagy and EMT. 
Concluding remarks 
 We have shown that inhibition of spleen tyrosine kinase results in inhibition of 
cell growth, potentially through disruption of mTORC1 signaling and autophagy. 
Furthermore, combination of SYK inhibition with MEK inhibition shows that these two 
inhibitors function in parallel pathways and have additive effects on both cell growth and 
autophagy. Pancreatic cancer is notoriously resistant to targeted therapeutics and the 
identification and investigation of additional potential therapeutic targets will be 
important to developing more effective treatments. SYK inhibition would not be very 
effective as a single therapy for PDAC, but combination with other inhibitors such as 
MEK may boost its efficacy. 
 In addition, the effects of autophagy activation in response to SYK and MEK 
inhibition requires further study, as this may reveal an exploitable weakness in PDAC 
therapeutic resistance and further enhance the effectiveness of SYK and MEK inhibition. 
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